{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "6e1a6c02",
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "import os\n",
    "import json\n",
    "import re\n",
    "os.getcwd()\n",
    "from bs4 import BeautifulSoup"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "5661be5c",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "CPIC_Guideline_for_abacavir_and_HLA_B\n",
      "CPIC_Guideline_for_aceclofenac_aspirin_diclofenac_dipyrone_indomethacin_lumiracoxib_nabumetone_naproxen_and_CYP2C9\n",
      "CPIC_Guideline_for_alfentanil_buprenorphine_codeine_fentanyl_hydrocodone_hydromorphone_levomethadone_morphine_naltrexone_remifentanil_sufentanil_tramadol_and_COMT_OPRM1\n",
      "CPIC_Guideline_for_allopurinol_and_HLA_B\n",
      "CPIC_Guideline_for_amikacin_gentamicin_kanamycin_paromomycin_plazomicin_streptomycin_tobramycin_and_MT_RNR1\n",
      "CPIC_Guideline_for_amitriptyline_and_CYP2C19_CYP2D6\n",
      "CPIC_Guideline_for_atazanavir_and_UGT1A1\n",
      "CPIC_Guideline_for_atomoxetine_and_CYP2D6\n",
      "CPIC_Guideline_for_azathioprine_and_NUDT15_TPMT\n",
      "CPIC_Guideline_for_capecitabine_and_DPYD\n",
      "CPIC_Guideline_for_carbamazepine_and_HLA_A_HLA_B\n",
      "CPIC_Guideline_for_celecoxib_flurbiprofen_ibuprofen_lornoxicam_and_CYP2C9\n",
      "CPIC_Guideline_for_citalopram_escitalopram_and_CYP2C19\n",
      "CPIC_Guideline_for_clomipramine_and_CYP2C19_CYP2D6\n",
      "CPIC_Guideline_for_clopidogrel_and_CYP2C19\n",
      "CPIC_Guideline_for_codeine_and_CYP2D6\n",
      "CPIC_Guideline_for_desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane_succinylcholine_and_CACNA1S_RYR1\n",
      "CPIC_Guideline_for_desipramine_and_CYP2D6\n",
      "CPIC_Guideline_for_dexlansoprazole_and_CYP2C19\n",
      "CPIC_Guideline_for_diclofenac_ibuprofen_and_CYP2C8\n",
      "CPIC_Guideline_for_doxepin_and_CYP2C19_CYP2D6\n",
      "CPIC_Guideline_for_efavirenz_and_CYP2B6\n",
      "CPIC_Guideline_for_esomeprazole_rabeprazole_and_CYP2C19\n",
      "CPIC_Guideline_for_fluorouracil_and_DPYD\n",
      "CPIC_Guideline_for_fluvoxamine_and_CYP2D6\n",
      "CPIC_Guideline_for_fosphenytoin_phenytoin_and_CYP2C9_HLA_B\n",
      "CPIC_Guideline_for_hydrocodone_and_CYP2D6\n",
      "CPIC_Guideline_for_imipramine_and_CYP2C19_CYP2D6\n",
      "CPIC_Guideline_for_ivacaftor_and_CFTR\n",
      "CPIC_Guideline_for_lansoprazole_omeprazole_pantoprazole_and_CYP2C19\n",
      "CPIC_Guideline_for_meloxicam_and_CYP2C9\n",
      "CPIC_Guideline_for_mercaptopurine_and_NUDT15_TPMT\n",
      "CPIC_Guideline_for_methadone_oxycodone_and_COMT_CYP2D6_OPRM1\n",
      "CPIC_Guideline_for_nortriptyline_and_CYP2D6\n",
      "CPIC_Guideline_for_ondansetron_and_CYP2D6\n",
      "CPIC_Guideline_for_oxcarbazepine_and_HLA_B\n",
      "CPIC_Guideline_for_paroxetine_and_CYP2D6\n",
      "CPIC_Guideline_for_peginterferon_alfa_2a_peginterferon_alfa_2b_ribavirin_and_IFNL3\n",
      "CPIC_Guideline_for_piroxicam_and_CYP2C9\n",
      "CPIC_Guideline_for_rasburicase_and_G6PD\n",
      "CPIC_Guideline_for_sertraline_and_CYP2C19\n",
      "CPIC_Guideline_for_simvastatin_and_SLCO1B1\n",
      "CPIC_Guideline_for_tacrolimus_and_CYP3A5\n",
      "CPIC_Guideline_for_tamoxifen_and_CYP2D6\n",
      "CPIC_Guideline_for_tegafur_and_DPYD\n",
      "CPIC_Guideline_for_tenoxicam_and_CYP2C9\n",
      "CPIC_Guideline_for_thioguanine_and_NUDT15_TPMT\n",
      "CPIC_Guideline_for_tramadol_and_CYP2D6\n",
      "CPIC_Guideline_for_trimipramine_and_CYP2C19_CYP2D6\n",
      "CPIC_Guideline_for_tropisetron_and_CYP2D6\n",
      "CPIC_Guideline_for_voriconazole_and_CYP2C19\n",
      "CPIC_Guideline_for_warfarin_and_CYP2C9_CYP4F2_VKORC1\n",
      "CPNDS_Guideline_for_carbamazepine_and_HLA_A\n",
      "CPNDS_Guideline_for_carbamazepine_and_HLA_B\n",
      "CPNDS_Guideline_for_cisplatin_and_TPMT\n",
      "CPNDS_Guideline_for_codeine_and_CYP2D6\n",
      "CPNDS_Guideline_for_daunorubicin_doxorubicin_and_RARG_SLC28A3_UGT1A6\n",
      "CPNDS_Guideline_for_tamoxifen_and_CYP2D6\n",
      "CPNDS_Guideline_for_warfarin_and_CYP2C9\n",
      "DPWG_Guideline_for_abacavir_and_HLA_B\n",
      "DPWG_Guideline_for_acenocoumarol_and_CYP2C9\n",
      "DPWG_Guideline_for_acenocoumarol_and_VKORC1\n",
      "DPWG_Guideline_for_amiodarone_and_CYP2D6\n",
      "DPWG_Guideline_for_amitriptyline_and_CYP2C19\n",
      "DPWG_Guideline_for_amitriptyline_and_CYP2D6\n",
      "DPWG_Guideline_for_aripiprazole_and_CYP2D6\n",
      "DPWG_Guideline_for_atenolol_and_CYP2D6\n",
      "DPWG_Guideline_for_atomoxetine_and_CYP2D6\n",
      "DPWG_Guideline_for_atorvastatin_and_SLCO1B1\n",
      "DPWG_Guideline_for_azathioprine_and_NUDT15\n",
      "DPWG_Guideline_for_azathioprine_and_TPMT\n",
      "DPWG_Guideline_for_bisoprolol_and_CYP2D6\n",
      "DPWG_Guideline_for_brexpiprazole_and_CYP2D6\n",
      "DPWG_Guideline_for_capecitabine_and_DPYD\n",
      "DPWG_Guideline_for_carvedilol_and_CYP2D6\n",
      "DPWG_Guideline_for_citalopram_and_CYP2C19\n",
      "DPWG_Guideline_for_citalopram_escitalopram_and_CYP2D6\n",
      "DPWG_Guideline_for_clomipramine_and_CYP2C19\n",
      "DPWG_Guideline_for_clomipramine_and_CYP2D6\n",
      "DPWG_Guideline_for_clonidine_and_CYP2D6\n",
      "DPWG_Guideline_for_clopidogrel_and_CYP2C19\n",
      "DPWG_Guideline_for_clozapine_and_CYP2D6\n",
      "DPWG_Guideline_for_codeine_and_CYP2D6\n",
      "DPWG_Guideline_for_disopyramide_and_CYP2D6\n",
      "DPWG_Guideline_for_doxepin_and_CYP2C19\n",
      "DPWG_Guideline_for_doxepin_and_CYP2D6\n",
      "DPWG_Guideline_for_duloxetine_and_CYP2D6\n",
      "DPWG_Guideline_for_efavirenz_and_CYP2B6\n",
      "DPWG_Guideline_for_eliglustat_and_CYP2D6\n",
      "DPWG_Guideline_for_escitalopram_and_CYP2C19\n",
      "DPWG_Guideline_for_esomeprazole_and_CYP2C19\n",
      "DPWG_Guideline_for_flecainide_and_CYP2D6\n",
      "DPWG_Guideline_for_flucloxacillin_and_HLA_B\n",
      "DPWG_Guideline_for_flucytosine_and_DPYD\n",
      "DPWG_Guideline_for_fluorouracil_and_DPYD\n",
      "DPWG_Guideline_for_fluoxetine_and_CYP2D6\n",
      "DPWG_Guideline_for_flupenthixol_and_CYP2D6\n",
      "DPWG_Guideline_for_fluphenazine_and_CYP2D6\n",
      "DPWG_Guideline_for_fluvastatin_and_SLCO1B1\n",
      "DPWG_Guideline_for_fluvoxamine_and_CYP2C19\n",
      "DPWG_Guideline_for_fluvoxamine_and_CYP2D6\n",
      "DPWG_Guideline_for_gefitinib_and_CYP2D6\n",
      "DPWG_Guideline_for_glibenclamide_and_CYP2C9\n",
      "DPWG_Guideline_for_gliclazide_and_CYP2C9\n",
      "DPWG_Guideline_for_glimepiride_and_CYP2C9\n",
      "DPWG_Guideline_for_haloperidol_and_CYP2D6\n",
      "DPWG_Guideline_for_imipramine_and_CYP2C19\n",
      "DPWG_Guideline_for_imipramine_and_CYP2D6\n",
      "DPWG_Guideline_for_irinotecan_and_UGT1A1\n",
      "DPWG_Guideline_for_lansoprazole_and_CYP2C19\n",
      "DPWG_Guideline_for_mercaptopurine_and_NUDT15\n",
      "DPWG_Guideline_for_mercaptopurine_and_TPMT\n",
      "DPWG_Guideline_for_methylphenidate_and_CYP2D6\n",
      "DPWG_Guideline_for_metoprolol_and_CYP2D6\n",
      "DPWG_Guideline_for_mirtazapine_and_CYP2C19\n",
      "DPWG_Guideline_for_mirtazapine_and_CYP2D6\n",
      "DPWG_Guideline_for_moclobemide_and_CYP2C19\n",
      "DPWG_Guideline_for_nortriptyline_and_CYP2D6\n",
      "DPWG_Guideline_for_olanzapine_and_CYP2D6\n",
      "DPWG_Guideline_for_omeprazole_and_CYP2C19\n",
      "DPWG_Guideline_for_oxycodone_and_CYP2D6\n",
      "DPWG_Guideline_for_pantoprazole_and_CYP2C19\n",
      "DPWG_Guideline_for_paroxetine_and_CYP2D6\n",
      "DPWG_Guideline_for_phenprocoumon_and_CYP2C9\n",
      "DPWG_Guideline_for_phenprocoumon_and_VKORC1\n",
      "DPWG_Guideline_for_phenytoin_and_CYP2C9\n",
      "DPWG_Guideline_for_pimozide_and_CYP2D6\n",
      "DPWG_Guideline_for_prasugrel_and_CYP2C19\n",
      "DPWG_Guideline_for_propafenone_and_CYP2D6\n",
      "DPWG_Guideline_for_quetiapine_and_CYP2D6\n",
      "DPWG_Guideline_for_quinidine_and_CYP2D6\n",
      "DPWG_Guideline_for_rabeprazole_and_CYP2C19\n",
      "DPWG_Guideline_for_ribavirin_and_HLA_B\n",
      "DPWG_Guideline_for_risperidone_and_CYP2D6\n",
      "DPWG_Guideline_for_sertraline_and_CYP2C19\n",
      "DPWG_Guideline_for_sertraline_and_CYP2D6\n",
      "DPWG_Guideline_for_simvastatin_and_SLCO1B1\n",
      "DPWG_Guideline_for_siponimod_and_CYP2C9\n",
      "DPWG_Guideline_for_sotalol_and_CYP2D6\n",
      "DPWG_Guideline_for_tacrolimus_and_CYP3A5\n",
      "DPWG_Guideline_for_tamoxifen_and_CYP2D6\n",
      "DPWG_Guideline_for_tegafur_and_DPYD\n",
      "DPWG_Guideline_for_thioguanine_and_NUDT15\n",
      "DPWG_Guideline_for_thioguanine_and_TPMT\n",
      "DPWG_Guideline_for_ticagrelor_and_CYP2C19\n",
      "DPWG_Guideline_for_tolbutamide_and_CYP2C9\n",
      "DPWG_Guideline_for_tramadol_and_CYP2D6\n",
      "DPWG_Guideline_for_venlafaxine_and_CYP2D6\n",
      "DPWG_Guideline_for_voriconazole_and_CYP2C19\n",
      "DPWG_Guideline_for_warfarin_and_CYP2C9\n",
      "DPWG_Guideline_for_warfarin_and_VKORC1\n",
      "DPWG_Guideline_for_zuclopenthixol_and_CYP2D6\n",
      "PRO_Guideline_for_acenocoumarol_fluindione_warfarin_and_CYP2C9_VKORC1\n",
      "PRO_Guideline_for_allopurinol_and_HLA_B\n",
      "PRO_Guideline_for_antidepressants_and_CYP2C19_CYP2D6\n",
      "PRO_Guideline_for_azathioprine_and_TPMT\n",
      "PRO_Guideline_for_capecitabine_fluorouracil_and_DPYD\n",
      "PRO_Guideline_for_clopidogrel_and_CYP2C19\n",
      "PRO_Guideline_for_hmg_coa_reductase_inhibitors_simvastatin_and_SLCO1B1\n",
      "PRO_Guideline_for_irinotecan_and_UGT1A1\n",
      "PRO_Guideline_for_ivacaftor_and_CFTR\n",
      "PRO_Guideline_for_mercaptopurine_and_TPMT\n",
      "PRO_Guideline_for_methotrexate_and_ABCB1_MTHFR_SLC19A1_SLCO1B1\n",
      "PRO_Guideline_for_tacrolimus_and_CYP3A4_CYP3A5\n",
      "PRO_Guideline_for_tamoxifen_and_CYP2D6\n",
      "(5440, 6)\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>guideline_institute</th>\n",
       "      <th>guideline_name</th>\n",
       "      <th>drug</th>\n",
       "      <th>gene</th>\n",
       "      <th>haplotype</th>\n",
       "      <th>term</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>Annotation of CPIC Guideline for abacavir and ...</td>\n",
       "      <td>abacavir</td>\n",
       "      <td>HLA_B</td>\n",
       "      <td>HLA-B*57:01:01</td>\n",
       "      <td>Presence</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>Annotation of CPIC Guideline for allopurinol a...</td>\n",
       "      <td>allopurinol</td>\n",
       "      <td>HLA_B</td>\n",
       "      <td>HLA-B*58:01</td>\n",
       "      <td>Presence</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>Annotation of CPIC Guideline for amikacin, gen...</td>\n",
       "      <td>amikacin</td>\n",
       "      <td>MT_RNR1</td>\n",
       "      <td>MT-RNR1 663A&gt;G</td>\n",
       "      <td>Uncertain risk of aminoglycoside-induced heari...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>Annotation of CPIC Guideline for amikacin, gen...</td>\n",
       "      <td>amikacin</td>\n",
       "      <td>MT_RNR1</td>\n",
       "      <td>MT-RNR1 669T&gt;C</td>\n",
       "      <td>Uncertain risk of aminoglycoside-induced heari...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>Annotation of CPIC Guideline for amikacin, gen...</td>\n",
       "      <td>amikacin</td>\n",
       "      <td>MT_RNR1</td>\n",
       "      <td>MT-RNR1 747A&gt;G</td>\n",
       "      <td>Uncertain risk of aminoglycoside-induced heari...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>Annotation of CPIC Guideline for amikacin, gen...</td>\n",
       "      <td>amikacin</td>\n",
       "      <td>MT_RNR1</td>\n",
       "      <td>MT-RNR1 786G&gt;A</td>\n",
       "      <td>Uncertain risk of aminoglycoside-induced heari...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>Annotation of CPIC Guideline for amikacin, gen...</td>\n",
       "      <td>amikacin</td>\n",
       "      <td>MT_RNR1</td>\n",
       "      <td>MT-RNR1 807A&gt;C</td>\n",
       "      <td>Uncertain risk of aminoglycoside-induced heari...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>Annotation of CPIC Guideline for amikacin, gen...</td>\n",
       "      <td>amikacin</td>\n",
       "      <td>MT_RNR1</td>\n",
       "      <td>MT-RNR1 807A&gt;G</td>\n",
       "      <td>Uncertain risk of aminoglycoside-induced heari...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>Annotation of CPIC Guideline for amikacin, gen...</td>\n",
       "      <td>amikacin</td>\n",
       "      <td>MT_RNR1</td>\n",
       "      <td>MT-RNR1 827A&gt;G</td>\n",
       "      <td>Normal risk of aminoglycoside-induced hearing ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>Annotation of CPIC Guideline for amikacin, gen...</td>\n",
       "      <td>amikacin</td>\n",
       "      <td>MT_RNR1</td>\n",
       "      <td>MT-RNR1 839A&gt;G</td>\n",
       "      <td>Uncertain risk of aminoglycoside-induced heari...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "  guideline_institute                                     guideline_name  \\\n",
       "0      CPIC_Guideline  Annotation of CPIC Guideline for abacavir and ...   \n",
       "1      CPIC_Guideline  Annotation of CPIC Guideline for allopurinol a...   \n",
       "2      CPIC_Guideline  Annotation of CPIC Guideline for amikacin, gen...   \n",
       "3      CPIC_Guideline  Annotation of CPIC Guideline for amikacin, gen...   \n",
       "4      CPIC_Guideline  Annotation of CPIC Guideline for amikacin, gen...   \n",
       "5      CPIC_Guideline  Annotation of CPIC Guideline for amikacin, gen...   \n",
       "6      CPIC_Guideline  Annotation of CPIC Guideline for amikacin, gen...   \n",
       "7      CPIC_Guideline  Annotation of CPIC Guideline for amikacin, gen...   \n",
       "8      CPIC_Guideline  Annotation of CPIC Guideline for amikacin, gen...   \n",
       "9      CPIC_Guideline  Annotation of CPIC Guideline for amikacin, gen...   \n",
       "\n",
       "          drug     gene       haplotype  \\\n",
       "0     abacavir    HLA_B  HLA-B*57:01:01   \n",
       "1  allopurinol    HLA_B     HLA-B*58:01   \n",
       "2     amikacin  MT_RNR1  MT-RNR1 663A>G   \n",
       "3     amikacin  MT_RNR1  MT-RNR1 669T>C   \n",
       "4     amikacin  MT_RNR1  MT-RNR1 747A>G   \n",
       "5     amikacin  MT_RNR1  MT-RNR1 786G>A   \n",
       "6     amikacin  MT_RNR1  MT-RNR1 807A>C   \n",
       "7     amikacin  MT_RNR1  MT-RNR1 807A>G   \n",
       "8     amikacin  MT_RNR1  MT-RNR1 827A>G   \n",
       "9     amikacin  MT_RNR1  MT-RNR1 839A>G   \n",
       "\n",
       "                                                term  \n",
       "0                                           Presence  \n",
       "1                                           Presence  \n",
       "2  Uncertain risk of aminoglycoside-induced heari...  \n",
       "3  Uncertain risk of aminoglycoside-induced heari...  \n",
       "4  Uncertain risk of aminoglycoside-induced heari...  \n",
       "5  Uncertain risk of aminoglycoside-induced heari...  \n",
       "6  Uncertain risk of aminoglycoside-induced heari...  \n",
       "7  Uncertain risk of aminoglycoside-induced heari...  \n",
       "8  Normal risk of aminoglycoside-induced hearing ...  \n",
       "9  Uncertain risk of aminoglycoside-induced heari...  "
      ]
     },
     "execution_count": 2,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "folder = \"guideline_annotation\"\n",
    "guideline_list = []\n",
    "haplotype_list = []\n",
    "term_list = []\n",
    "drug_list = []\n",
    "gene_list = []\n",
    "guideline_name_list = []\n",
    "\n",
    "for path in os.listdir(folder):\n",
    "    if path.endswith(\".json\") and \"Annotation_of_\" in path:\n",
    "        with open(os.path.join(folder, path), \"r\", encoding=\"utf-8\") as f:\n",
    "            guideline_dict = json.load(f)\n",
    "\n",
    "        path = path.replace(\"Annotation_of_\", \"\").replace(\".json\", \"\")\n",
    "        try:\n",
    "            guideline, drug_gene = path.split(\"_for_\")\n",
    "        except:\n",
    "            continue\n",
    "        drugs, genes = drug_gene.split(\"_and_\")\n",
    "        drugs = list(filter(lambda x: x!= \"\", [x.strip() for x in drugs.split(\"_\")]))\n",
    "\n",
    "        tmp_haplotype_list = []\n",
    "        tmp_term_list = []\n",
    "        for guideline_gene in guideline_dict[\"guideline\"][\"guidelineGenes\"]:\n",
    "            for allele in guideline_gene[\"alleles\"]:\n",
    "                if \"haplotype\" in allele.keys():\n",
    "                    tmp_haplotype_list.append(allele[\"haplotype\"][\"symbol\"])\n",
    "                    tmp_term_list.append(allele[\"function\"][\"term\"])\n",
    "        \n",
    "        guideline_name = guideline_dict[\"guideline\"][\"name\"]\n",
    "        \n",
    "        guideline_name_list.extend([guideline_name] * len(tmp_haplotype_list) * len(drugs))\n",
    "        guideline_list.extend([guideline] * len(tmp_haplotype_list) * len(drugs))\n",
    "        gene_list.extend([genes] * len(tmp_haplotype_list) * len(drugs))\n",
    "        # data alignment\n",
    "        for drug in drugs:\n",
    "            drug_list.extend([drug] * len(tmp_haplotype_list))\n",
    "            haplotype_list.extend(tmp_haplotype_list)\n",
    "            term_list.extend(tmp_term_list)\n",
    "        print(path)\n",
    "        \n",
    "\n",
    "df_guideline = pd.DataFrame({\n",
    "    \"guideline_institute\": guideline_list,\n",
    "    \"guideline_name\": guideline_name_list,\n",
    "    \"drug\": drug_list,\n",
    "    \"gene\": gene_list,\n",
    "    \"haplotype\": haplotype_list,\n",
    "    \"term\": term_list\n",
    "})\n",
    "\n",
    "print(df_guideline.shape)\n",
    "df_guideline[:10]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "0ff7206f",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'DPYD', 'CYP3A5', 'UGT1A1', 'TPMT', 'CACNA1S', 'RYR1', 'HLA_B', 'CYP2C9', 'CFTR', 'IFNL3', 'MT_RNR1', 'CYP2C19', 'CYP2D6', 'NUDT15', 'SLCO1B1', 'HLA_A', 'CYP2B6', 'G6PD'}\n"
     ]
    }
   ],
   "source": [
    "print(set(['CYP2C19', 'CYP2D6', 'NUDT15', 'TPMT', 'CYP2C9', 'CFTR', 'CYP2D6', 'G6PD',\n",
    "           'SLCO1B1', 'UGT1A1', 'DPYD', 'HLA_B', 'HLA_A', 'HLA_B', 'CYP2C9', 'HLA_B',\n",
    "           'NUDT15', 'CYP3A5', 'IFNL3', 'CYP2C19', 'CYP2B6', 'MT_RNR1', 'CACNA1S', 'RYR1']))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "56e658f8",
   "metadata": {},
   "outputs": [],
   "source": [
    "df_guideline.assign(\n",
    "    data_source=[\"guideline\"] * len(df_guideline)\n",
    ").to_csv(\"processed/guideline_drug_variant_annotation.csv\", index=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "9b93e4f7",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "7d7614df",
   "metadata": {},
   "outputs": [],
   "source": [
    "html = \"<h3 id=\\\"november-2018-update\\\">November 2018 Update</h3>\\n<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for aripiprazole based on CYP2D6 genotype. They recommend reducing maximum dose of aripiprazole for CYP2D6 poor metabolizer (PM).</p>\\n<p><em>Wording in table taken from the <a href=\\\"https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\\\">Dutch guidelines November 2018 update</a></em></p>\\n<table class=\\\"table\\\">\\n<thead>\\n<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>\\n</thead>\\n<tbody>\\n<tr><td>CYP2D6 UM</td><td>aripiprazole</td><td>-</td><td>NO action is needed for this gene-drug interaction. The genetic variation decreases the plasma concentration of the sum of aripiprazole and the active metabolite dehydroaripiprazole to a limited degree. There is no evidence that this increases the risk of reduced effectiveness.</td></tr>\\n<tr><td>CYP2D6 IM</td><td>aripiprazole</td><td>-</td><td>NO action is needed for this gene-drug interaction.The genetic variation increases the plasma concentration of the sum of aripiprazole and the active metabolite dehydroaripiprazole to a limited degree. There is insufficient evidence that this increases the risk of side effects.</td></tr>\\n<tr><td>CYP2D6 PM</td><td>aripiprazole</td><td>The risk of side effects is increased. The genetic variation leads to an increase in the sum of the plasma concentrations of aripiprazole and the active metabolite.</td><td>Administer no more than 10 mg/day or 300 mg/month (67-75% of the standard maximum dose of aripiprazole).</td></tr>\\n</tbody>\\n</table>\\n<p><a rel=\\\"noopener noreferrer\\\" href=\\\"https://www.g-standaard.nl/risicoanalyse/B0001543.PDF\\\" target=\\\"_blank\\\">Read for more information about this recommendation</a>, <a rel=\\\"noopener noreferrer\\\" href=\\\"https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\\\" target=\\\"_blank\\\">Read about gene information from DPWG</a></p>\\n<h3 id=\\\"2011-guideline\\\">2011 Guideline</h3>\\n<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) has evaluated therapeutic dose recommendations for aripiprazole based on CYP2D6 genotypes [Article:<a href=\\\"/pmid/21412232\\\">21412232</a>].  They recommend reducing maximum dose of aripiprazole for patients carrying poor metabolizer alleles of CYP2D6.</p>\\n<table class=\\\"table\\\">\\n<thead>\\n<tr><th>Phenotype (Genotype)</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>\\n</thead>\\n<tbody>\\n<tr><td>PM (two inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) alleles)</td><td>Reduce maximum dose to 10 mg/day (67% of the maximum recommended daily dose).</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): long-standing discomfort (48-168 hr) without permanent injury e.g. failure of therapy with tricyclic antidepressants, atypical antipsychotic drugs; extrapyramidal side effects; parkinsonism; ADE resulting from increased bioavailability of tricyclic antidepressants, metoprolol, propafenone (central effects e.g. dizziness); INR 4.5-6.0; neutropenia 1.0-1.5x109/l; leucopenia 2.0-3.0x109/l; thrombocytopenia 50-75x109/l.</td></tr>\\n<tr><td>IM (two decreased-activity (*9, *10, *17, *29, *36, *41) alleles or carrying one active (*1, *2, *33, *35) and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele, or carrying one decreased-activity (*9, *10, *17, *29, *36, *41) allele and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele)</td><td>No recommendations.</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Minor clinical effect (S): QTc prolongation (&lt;450 ms female, &lt;470 ms male); INR increase &lt; 4.5; Kinetic effect (S)</td></tr>\\n<tr><td>UM (a gene duplication in absence of inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) or decreased-activity (*9, *10, *17, *29, *36, *41) alleles)</td><td>No recommendations.</td><td>--</td><td>--</td></tr>\\n</tbody>\\n</table>\\n<ul>\\n<li>*See <a href=\\\"http://www.pharmgkb.org/page/dpwg\\\">Methods </a> or [Article:<a href=\\\"/pmid/18253145\\\">18253145</a>] for definition of &quot;good quality.&quot;</li>\\n<li>S: statistically significant difference.</li>\\n<li>Please see attached PDF for detailed information about the evaluated studies: <a href=\\\"https://api.pharmgkb.org/v1/download/file/attachment/aripiprazole_CYP2D6_271111.pdf\\\">Aripiprazole CYP2D6 </a></li>\\n</ul>\\n\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "0091fb57",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "1ee9f324",
   "metadata": {},
   "outputs": [],
   "source": [
    "soup = BeautifulSoup(html, \"html.parser\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "8dc6c090",
   "metadata": {},
   "outputs": [],
   "source": [
    "list_header = []\n",
    "header = soup.find_all(\"table\")[0].find(\"tr\")\n",
    "for items in header:\n",
    "    try:\n",
    "        list_header.append(items.get_text())\n",
    "    except:\n",
    "        continue"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "44334479",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['Allele/Genotype/Phenotype', 'Drug', 'Description', 'Recommendation']"
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "list_header"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "ab4c8f48",
   "metadata": {},
   "outputs": [],
   "source": [
    "HTML_data = soup.find_all(\"table\")[0].find_all(\"tr\")[1:]\n",
    "data = []\n",
    "\n",
    "for element in HTML_data:\n",
    "    sub_data = []\n",
    "    for sub_element in element:\n",
    "        try:\n",
    "            sub_data.append(sub_element.get_text())\n",
    "        except:\n",
    "            continue\n",
    "    data.append(sub_data)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "170c5cc3",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[['CYP2D6 UM',\n",
       "  'aripiprazole',\n",
       "  '-',\n",
       "  'NO action is needed for this gene-drug interaction. The genetic variation decreases the plasma concentration of the sum of aripiprazole and the active metabolite dehydroaripiprazole to a limited degree. There is no evidence that this increases the risk of reduced effectiveness.'],\n",
       " ['CYP2D6 IM',\n",
       "  'aripiprazole',\n",
       "  '-',\n",
       "  'NO action is needed for this gene-drug interaction.The genetic variation increases the plasma concentration of the sum of aripiprazole and the active metabolite dehydroaripiprazole to a limited degree. There is insufficient evidence that this increases the risk of side effects.'],\n",
       " ['CYP2D6 PM',\n",
       "  'aripiprazole',\n",
       "  'The risk of side effects is increased. The genetic variation leads to an increase in the sum of the plasma concentrations of aripiprazole and the active metabolite.',\n",
       "  'Administer no more than 10 mg/day or 300 mg/month (67-75% of the standard maximum dose of aripiprazole).']]"
      ]
     },
     "execution_count": 12,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "6cb45a0a",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Allele/Genotype/Phenotype</th>\n",
       "      <th>Drug</th>\n",
       "      <th>Description</th>\n",
       "      <th>Recommendation</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>CYP2D6 UM</td>\n",
       "      <td>aripiprazole</td>\n",
       "      <td>-</td>\n",
       "      <td>NO action is needed for this gene-drug interac...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>CYP2D6 IM</td>\n",
       "      <td>aripiprazole</td>\n",
       "      <td>-</td>\n",
       "      <td>NO action is needed for this gene-drug interac...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>CYP2D6 PM</td>\n",
       "      <td>aripiprazole</td>\n",
       "      <td>The risk of side effects is increased. The gen...</td>\n",
       "      <td>Administer no more than 10 mg/day or 300 mg/mo...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "  Allele/Genotype/Phenotype          Drug  \\\n",
       "0                 CYP2D6 UM  aripiprazole   \n",
       "1                 CYP2D6 IM  aripiprazole   \n",
       "2                 CYP2D6 PM  aripiprazole   \n",
       "\n",
       "                                         Description  \\\n",
       "0                                                  -   \n",
       "1                                                  -   \n",
       "2  The risk of side effects is increased. The gen...   \n",
       "\n",
       "                                      Recommendation  \n",
       "0  NO action is needed for this gene-drug interac...  \n",
       "1  NO action is needed for this gene-drug interac...  \n",
       "2  Administer no more than 10 mg/day or 300 mg/mo...  "
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pd.DataFrame(data = data, columns = list_header)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "0a8ec0c1",
   "metadata": {},
   "outputs": [],
   "source": [
    "def parse_tables(html, gene, drug, organization, link):\n",
    "    # save columns which contain these pharses\n",
    "    column_template = [\"phenotype\", \"diplotype\", \"genotype\", \"implication\", \"description\", \"recommendation\", \"dosing\"]\n",
    "    soup = BeautifulSoup(html, \"html.parser\")\n",
    "    tables = soup.find_all(\"table\")\n",
    "    titles = soup.find_all(\"h3\")\n",
    "    df_list = []\n",
    "    for i in range(len(tables)):\n",
    "        try:\n",
    "            table = tables[i]\n",
    "            title = titles[i].get_text()\n",
    "        except Exception as e:\n",
    "            print(\"missing title, gene {}, drug {}, organization {}\".format(gene, drug, organization))\n",
    "            continue\n",
    "        list_header = []\n",
    "        header = table.find(\"tr\")\n",
    "        for items in header:\n",
    "            try:\n",
    "                t = items.get_text()\n",
    "                if t == \"\\n\":\n",
    "                    continue\n",
    "                list_header.append(t)\n",
    "            except:\n",
    "                continue\n",
    "\n",
    "        HTML_data = table.find_all(\"tr\")[1:]\n",
    "        data = []\n",
    "        for element in HTML_data:\n",
    "            sub_data = []\n",
    "            for sub_element in element:\n",
    "                try:\n",
    "                    t = sub_element.get_text()\n",
    "                    if t == \"\\n\":\n",
    "                        continue\n",
    "                    sub_data.append(t)\n",
    "                except:\n",
    "                    continue\n",
    "            data.append(sub_data)\n",
    "\n",
    "        try:\n",
    "            df_tmp = pd.DataFrame(data=data, columns=list_header)\n",
    "            save_column = []\n",
    "            for column in df_tmp.columns:\n",
    "                if any([True if x in column.lower() else False for x in column_template]):\n",
    "                    save_column.append(column)\n",
    "            df_tmp = df_tmp[save_column]\n",
    "            \n",
    "            df_tmp = df_tmp.assign(\n",
    "                gene=[gene] * len(df_tmp)\n",
    "            ).assign(\n",
    "                drug=[drug] * len(df_tmp)\n",
    "            ).assign(\n",
    "                organization=[organization] * len(df_tmp)\n",
    "            ).assign(\n",
    "                title=[title] * len(df_tmp)\n",
    "            ).assign(\n",
    "                link=[link] * len(df_tmp)\n",
    "            )\n",
    "            df_list.append(df_tmp)\n",
    "        except Exception as e:\n",
    "            print(\"parsing html failed, gene {}, drug {}, organization {}\".format(gene, drug, organization))\n",
    "            continue\n",
    "    return df_list\n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "fdee11e7",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "missing title, gene CYP2D6, drug tamoxifen, organization CPNDS_Guideline\n",
      "missing title, gene CYP2D6, drug haloperidol, organization DPWG_Guideline\n",
      "missing title, gene CYP2D6, drug imipramine, organization DPWG_Guideline\n",
      "missing title, gene CYP2D6, drug metoprolol, organization DPWG_Guideline\n",
      "missing title, gene CYP2D6, drug nortriptyline, organization DPWG_Guideline\n",
      "missing title, gene CYP2D6, drug paroxetine, organization DPWG_Guideline\n",
      "missing title, gene CYP2D6, drug propafenone, organization DPWG_Guideline\n",
      "missing title, gene CYP2C9_VKORC1, drug acenocoumarol_fluindione_warfarin, organization PRO_Guideline\n"
     ]
    }
   ],
   "source": [
    "tables = []\n",
    "folder = \"guideline_annotation\"\n",
    "for path in os.listdir(folder):\n",
    "    if path.endswith(\".json\") and \"Annotation_of_\" in path:\n",
    "        with open(os.path.join(folder, path), \"r\", encoding=\"utf-8\") as f:\n",
    "            guideline_dict = json.load(f)\n",
    "            \n",
    "        path = path.replace(\"Annotation_of_\", \"\").replace(\".json\", \"\")\n",
    "        try:\n",
    "            guideline, drug_gene = path.split(\"_for_\")\n",
    "        except:\n",
    "            continue\n",
    "        drugs, genes = drug_gene.split(\"_and_\")\n",
    "        html = guideline_dict[\"guideline\"][\"textMarkdown\"][\"html\"]\n",
    "        link = guideline_dict[\"guideline\"][\"@id\"]\n",
    "        \n",
    "        tables.extend(parse_tables(guideline_dict[\"guideline\"][\"textMarkdown\"][\"html\"], \n",
    "                                   gene=genes, drug=drugs, organization=guideline, link=link))\n",
    "        "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "fbd91738",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "8e8d0f78",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['phenotype',\n",
       " 'diplotype',\n",
       " 'genotype',\n",
       " 'implication',\n",
       " 'description',\n",
       " 'recommendation']"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "[\"phenotype\", \"diplotype\", \"genotype\", \"implication\", \"description\", \"recommendation\"]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "de4c86fd",
   "metadata": {},
   "outputs": [],
   "source": [
    "phenotype_category_list = []\n",
    "phenotype_list = []\n",
    "diplotype_list = []\n",
    "genotype_list = []\n",
    "implication_list = []\n",
    "description_list = []\n",
    "recommendation_list = []\n",
    "dosing_list = []\n",
    "gene_list = []\n",
    "drug_list = []\n",
    "organization_list = []\n",
    "title_list = []\n",
    "link_list = []\n",
    "for table in tables:\n",
    "    phenotype_column = \"\"\n",
    "    diplotype_column = \"\"\n",
    "    genotype_column = \"\"\n",
    "    implication_column = \"\"\n",
    "    description_column = \"\"\n",
    "    recommendation_column = \"\"\n",
    "    dosing_column = \"\"\n",
    "    for col in table.columns:\n",
    "        if \"phenotype\" in col.lower():\n",
    "            phenotype_column = col\n",
    "        if \"diplotype\" in col.lower():\n",
    "            diplotype_column = col\n",
    "        if \"genotype\" in col.lower():\n",
    "            genotype_column = col\n",
    "        if \"implication\" in col.lower():\n",
    "            implication_column = col\n",
    "        if \"description\" in col.lower():\n",
    "            description_column = col\n",
    "        if \"recommendation\" in col.lower() and \"classification\" not in col.lower():\n",
    "            recommendation_column = col\n",
    "        if \"dosing\" in col.lower():\n",
    "            dosing_column = col\n",
    "            \n",
    "    for index, row in table.iterrows():\n",
    "        if phenotype_column != \"\":\n",
    "            phenotype = row[phenotype_column]\n",
    "        else:\n",
    "            continue\n",
    "        \n",
    "        if diplotype_column != \"\":\n",
    "            diplotype = row[diplotype_column]\n",
    "        else:\n",
    "            diplotype = \"\"\n",
    "        \n",
    "        if genotype_column != \"\":\n",
    "            genotype = row[genotype_column]\n",
    "        else:\n",
    "            genotype = \"\"\n",
    "\n",
    "        if implication_column != \"\":\n",
    "            implication = row[implication_column]\n",
    "        else:\n",
    "            implication = \"\"\n",
    "            \n",
    "        if description_column != \"\":\n",
    "            description = row[description_column]\n",
    "        else:\n",
    "            description = \"\"\n",
    "            \n",
    "        if recommendation_column != \"\":\n",
    "            recommendation = row[recommendation_column]\n",
    "        else:\n",
    "            recommendation = \"\"\n",
    "            \n",
    "        if dosing_column != \"\":\n",
    "            dosing = row[dosing_column]\n",
    "        else:\n",
    "            dosing = \"\"\n",
    "        \n",
    "        gene = row[\"gene\"]\n",
    "        drug = row[\"drug\"]\n",
    "        organization = row[\"organization\"]\n",
    "        title = row[\"title\"]\n",
    "\n",
    "        if any([True if x in phenotype.lower() and \"meta\" in phenotype.lower() else False \\\n",
    "                for x in [\"intermediate\", \"normal\", \"poor\", \"rapid\", \"ultrarapid\", \"extensive\"]]) or \\\n",
    "           any(True if x in phenotype else False \\\n",
    "                for x in [\"IM\", \"PM\", \"UM\", \"NM\", \"RM\", \"EM\"]):\n",
    "            pass\n",
    "        else:\n",
    "            continue\n",
    "            \n",
    "        if genotype == \"\" and implication == \"\" and description == \"\" and recommendation == \"\" and dosing == \"\":\n",
    "            continue\n",
    "            \n",
    "        if \"_\" in gene:\n",
    "            genes = gene.split(\"_\")\n",
    "            filtered_gene = list(filter(lambda x: x in phenotype, genes))\n",
    "            if len(filtered_gene) > 0:\n",
    "                gene = filtered_gene[0] \n",
    "                \n",
    "        if \"Drug\" in table.columns and row[\"Drug\"] != \"\":\n",
    "            drug = row[\"Drug\"]\n",
    "        elif \"_\" in drug:\n",
    "            drugs = drug.split(\"_\")\n",
    "            filtered_drug = list(filter(lambda x: x in phenotype or x in recommendation or x in implication, drugs))\n",
    "            if len(filtered_drug) > 0:\n",
    "                drug = filtered_drug[0] \n",
    "        \n",
    "        phenotype_category = \"\"\n",
    "        if \"poor\" in phenotype.lower() or \"PM\" in phenotype:\n",
    "            phenotype_category = \"Poor Metabolizer\"\n",
    "        elif \"intermediate\" in phenotype.lower() or \"IM\" in phenotype:\n",
    "            phenotype_category = \"Intermediate metabolizer\"\n",
    "        elif \"normal\" in phenotype.lower() or \"NM\" in phenotype:\n",
    "            phenotype_category = \"Normal metabolizer\"\n",
    "        elif (\"rapid\" in phenotype.lower() and \"ultra\" not in phenotype.lower()) or \"RM\" in phenotype:\n",
    "            phenotype_category = \"Rapid metabolizer\"\n",
    "        elif (\"rapid\" in phenotype.lower() and \"ultra\" in phenotype.lower()) or \"UM\" in phenotype:\n",
    "            phenotype_category = \"Ultrarapid metabolizer\"\n",
    "        elif \"extensive\" in phenotype.lower() or \"EM\" in phenotype:\n",
    "            phenotype_category = \"Extensive metabolizer\"\n",
    "            \n",
    "        phenotype_category_list.append(phenotype_category)\n",
    "        phenotype_list.append(phenotype)\n",
    "        diplotype_list.append(diplotype)\n",
    "        genotype_list.append(genotype)\n",
    "        implication_list.append(implication)\n",
    "        description_list.append(description)\n",
    "        recommendation_list.append(recommendation)\n",
    "        dosing_list.append(dosing)\n",
    "        gene_list.append(gene)\n",
    "        drug_list.append(drug)\n",
    "        organization_list.append(organization)\n",
    "        title_list.append(title)\n",
    "        link_list.append(row[\"link\"])\n",
    "            \n",
    "df_pheno_drug = pd.DataFrame({\n",
    "    \"phenotype_category\": phenotype_category_list,\n",
    "    \"phenotype\": phenotype_list,\n",
    "    \"diplotype\": diplotype_list,\n",
    "    \"genotype\": genotype_list,\n",
    "    \"implication\": implication_list,\n",
    "    \"description\": description_list,\n",
    "    \"recommendation\": recommendation_list,\n",
    "    \"dosing\": dosing_list,\n",
    "    \"gene\": gene_list,\n",
    "    \"drug\": drug_list,\n",
    "    \"organization\": organization_list,\n",
    "    \"title\": title_list,\n",
    "    \"link\": link_list,\n",
    "    \"data_source\": [\"guildeline\"] * len(link_list)\n",
    "})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "id": "17c19998",
   "metadata": {},
   "outputs": [],
   "source": [
    "# for diplotype\n",
    "phenotype_category_list = [] \n",
    "phenotype_list = []\n",
    "diplotype_list = []\n",
    "genotype_list = []\n",
    "implication_list = []\n",
    "description_list = []\n",
    "recommendation_list = []\n",
    "gene_list = []\n",
    "drug_list = []\n",
    "organization_list = []\n",
    "title_list = []\n",
    "link_list = []\n",
    "\n",
    "for index, row in df_pheno_drug.iterrows():\n",
    "    diplotype = row[\"diplotype\"]\n",
    "    diplotypes = re.split(\",|;| \", diplotype)\n",
    "    diplotypes = list(filter(lambda x: x != \"\" and x.count(\"*\") == 2, diplotypes))\n",
    "    if len(diplotypes) == 0:\n",
    "        continue\n",
    "        \n",
    "    for dip in diplotypes:\n",
    "        dip_name = \"{} {}\".format(row[\"gene\"], dip)\n",
    "        recommendation = row[\"dosing\"] if row[\"dosing\"] != \"\" else row[\"recommendation\"]\n",
    "        phenotype_category_list.append(row[\"phenotype_category\"])\n",
    "        phenotype_list.append(row[\"phenotype\"])\n",
    "        diplotype_list.append(dip_name)\n",
    "        genotype_list.append(row[\"genotype\"])\n",
    "        implication_list.append(row[\"implication\"])\n",
    "        description_list.append(row[\"description\"])\n",
    "        recommendation_list.append(row[\"recommendation\"])\n",
    "        gene_list.append(row[\"gene\"])\n",
    "        drug_list.append(row[\"drug\"])\n",
    "        organization_list.append(row[\"organization\"])\n",
    "        title_list.append(row[\"title\"])\n",
    "        link_list.append(row[\"link\"])\n",
    "        \n",
    "pd.DataFrame({\n",
    "    \"phenotype_category\": phenotype_category_list,\n",
    "    \"phenotype\": phenotype_list,\n",
    "    \"diplotype\": diplotype_list,\n",
    "    \"genotype\": genotype_list,\n",
    "    \"implication\": implication_list,\n",
    "    \"description\": description_list,\n",
    "    \"recommendation\": recommendation_list,\n",
    "    \"gene\": gene_list,\n",
    "    \"drug\": drug_list,\n",
    "    \"organization\": organization_list,\n",
    "    \"title\": title_list,\n",
    "    \"link\": link_list,\n",
    "    \"data_source\": [\"guildeline\"] * len(link_list)\n",
    "}).to_csv(\"processed/diplotype_drug_relation.csv\", index=False)\n",
    "\n",
    "df_pheno_drug.to_csv(\"processed/phenotype_drug_relation.csv\", index=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 218,
   "id": "d532677b",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "473"
      ]
     },
     "execution_count": 218,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(df_pheno_drug)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "b2386caa",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 229,
   "id": "a8349fd8",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "1892"
      ]
     },
     "execution_count": 229,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(link_list)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "860082f8",
   "metadata": {
    "scrolled": false
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>node</th>\n",
       "      <th>count</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>diplotype</td>\n",
       "      <td>16574</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>chemical</td>\n",
       "      <td>932</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>gene</td>\n",
       "      <td>2013</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>haplotype</td>\n",
       "      <td>1526</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>rsID</td>\n",
       "      <td>6412</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>nmpa_drug</td>\n",
       "      <td>33608</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>total</td>\n",
       "      <td>61065</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "        node  count\n",
       "0  diplotype  16574\n",
       "1   chemical    932\n",
       "2       gene   2013\n",
       "3  haplotype   1526\n",
       "4       rsID   6412\n",
       "5  nmpa_drug  33608\n",
       "6      total  61065"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pd.DataFrame({\n",
    "    \"node\": [\"diplotype\", \"chemical\", \"gene\", \"haplotype\", \"rsID\", \"nmpa_drug\", \"total\"],\n",
    "    \"count\": [16574, 932, 2013, 1526, 6412, 33608, 61065]\n",
    "})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "b7119569",
   "metadata": {
    "scrolled": false
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>edge</th>\n",
       "      <th>count</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>clinical_annotation</td>\n",
       "      <td>8318</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>diplotype_consist_of</td>\n",
       "      <td>32420</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>diplotype_metabolizer</td>\n",
       "      <td>10291</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>drug_label</td>\n",
       "      <td>29628</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>guideline_annotation</td>\n",
       "      <td>5797</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>haplotype_rsID_related</td>\n",
       "      <td>785</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>mutation_at</td>\n",
       "      <td>8183</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>research_annotation</td>\n",
       "      <td>4291</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>drug_consist_of</td>\n",
       "      <td>33608</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>total</td>\n",
       "      <td>133321</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                     edge   count\n",
       "0     clinical_annotation    8318\n",
       "1    diplotype_consist_of   32420\n",
       "2   diplotype_metabolizer   10291\n",
       "3              drug_label   29628\n",
       "4    guideline_annotation    5797\n",
       "5  haplotype_rsID_related     785\n",
       "6             mutation_at    8183\n",
       "7     research_annotation    4291\n",
       "8         drug_consist_of   33608\n",
       "9                   total  133321"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pd.DataFrame({\n",
    "    \"edge\": [\"clinical_annotation\", \"diplotype_consist_of\", \"diplotype_metabolizer\", \"drug_label\",\n",
    "             \"guideline_annotation\", \"haplotype_rsID_related\", \"mutation_at\", \"research_annotation\",\n",
    "             \"drug_consist_of\", \"total\"],\n",
    "    \"count\": [8318, 32420, 10291, 29628, 5797, 785, 8183, 4291, 33608, 133321]\n",
    "})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "046c9bbc",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>phenotype_category</th>\n",
       "      <th>phenotype</th>\n",
       "      <th>diplotype</th>\n",
       "      <th>genotype</th>\n",
       "      <th>implication</th>\n",
       "      <th>description</th>\n",
       "      <th>recommendation</th>\n",
       "      <th>dosing</th>\n",
       "      <th>gene</th>\n",
       "      <th>drug</th>\n",
       "      <th>organization</th>\n",
       "      <th>title</th>\n",
       "      <th>link</th>\n",
       "      <th>data_source</th>\n",
       "      <th>update_date</th>\n",
       "      <th>variant</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td></td>\n",
       "      <td>Very low risk of hypersensitivity (constitutes...</td>\n",
       "      <td>*X/*X c</td>\n",
       "      <td>Absence of *57:01 alleles (reported as \"negati...</td>\n",
       "      <td>Low or reduced risk of abacavir hypersensitivity</td>\n",
       "      <td></td>\n",
       "      <td>Use abacavir per standard dosing guidelines</td>\n",
       "      <td></td>\n",
       "      <td>HLA_B</td>\n",
       "      <td>abacavir</td>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>May 2014 Update</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td></td>\n",
       "      <td>High risk of hypersensitivity (~6% of patients)</td>\n",
       "      <td>*57:01/*X c *57:01/*57:01</td>\n",
       "      <td>Presence of at least one *57:01 allele (report...</td>\n",
       "      <td>Significantly increased risk of abacavir hyper...</td>\n",
       "      <td></td>\n",
       "      <td>Abacavir is not recommended</td>\n",
       "      <td></td>\n",
       "      <td>HLA_B</td>\n",
       "      <td>abacavir</td>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>May 2014 Update</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td></td>\n",
       "      <td>Low or reduced risk of allopurinol SCAR</td>\n",
       "      <td>*X/*X a</td>\n",
       "      <td>Absence of *58:01 alleles (reported as \"negati...</td>\n",
       "      <td>Low or reduced risk of allopurinol SCAR</td>\n",
       "      <td></td>\n",
       "      <td>Use allopurinol per standard dosing guidelines</td>\n",
       "      <td></td>\n",
       "      <td>HLA_B</td>\n",
       "      <td>allopurinol</td>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>January 2016 Update</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td></td>\n",
       "      <td>Significantly increased risk of allopurinol SCAR</td>\n",
       "      <td>*58:01/*X a *58:01/*58:01</td>\n",
       "      <td>Presence of at least one *58:01 allele (report...</td>\n",
       "      <td>Significantly increased risk of allopurinol SCAR</td>\n",
       "      <td></td>\n",
       "      <td>Allopurinol is contraindicated</td>\n",
       "      <td></td>\n",
       "      <td>HLA_B</td>\n",
       "      <td>allopurinol</td>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>January 2016 Update</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td></td>\n",
       "      <td>Homozygous for alleles other than HLA-B*15:02 ...</td>\n",
       "      <td>*X/*X b*Y/*Y c</td>\n",
       "      <td>Non-carrier of HLA-B*15:02 or HLA-A*31:01.  No...</td>\n",
       "      <td>Normal or reduced risk of carbamazepine-induce...</td>\n",
       "      <td></td>\n",
       "      <td>Use carbamazepine per standard dosing guidelin...</td>\n",
       "      <td></td>\n",
       "      <td>HLA</td>\n",
       "      <td>carbamazepine</td>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>December 2017</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td></td>\n",
       "      <td>Heterozygote or homozygous for HLA-A*31:01 and...</td>\n",
       "      <td>*X/*X b*31:01/*Y c*31:01/*31:01</td>\n",
       "      <td>Carrier of HLA-A*31:01.  One or two *31:01 all...</td>\n",
       "      <td>Increased risk of carbamazepine-induced SJS/TE...</td>\n",
       "      <td></td>\n",
       "      <td>A. If patient is carbamazepine-naive and alter...</td>\n",
       "      <td></td>\n",
       "      <td>HLA</td>\n",
       "      <td>carbamazepine</td>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>December 2017</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td></td>\n",
       "      <td>Heterozygote or homozygous for HLA-B*15:02 and...</td>\n",
       "      <td>*15:02/*X b*15:02/*15:02</td>\n",
       "      <td>Carrier of HLA-B*15:02.  One or two *15:02 all...</td>\n",
       "      <td>Increased risk of carbamazepine-induced SJS/TEN</td>\n",
       "      <td></td>\n",
       "      <td>A. If patient is carbamazepine-naive, do not u...</td>\n",
       "      <td></td>\n",
       "      <td>HLA</td>\n",
       "      <td>carbamazepine</td>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>December 2017</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td></td>\n",
       "      <td>Malignant Hyperthermia susceptible</td>\n",
       "      <td></td>\n",
       "      <td>An individual heterozygousb for a RYR1 or CACN...</td>\n",
       "      <td>Individuals are at increased risk of developin...</td>\n",
       "      <td></td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>CACNA1S_RYR1</td>\n",
       "      <td>desflurane</td>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>November 2018</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "      <td>RYR1 c.103T&gt;C; p.(Cys35Arg), RYR1 c.130C&gt;T; p....</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td></td>\n",
       "      <td>Uncertain susceptibility</td>\n",
       "      <td></td>\n",
       "      <td>An individual negative for a RYR1 or CACNA1S m...</td>\n",
       "      <td>These results do not eliminate the chance that...</td>\n",
       "      <td></td>\n",
       "      <td>Clinical findings, family history, further gen...</td>\n",
       "      <td>Clinical findings, family history, further gen...</td>\n",
       "      <td>CACNA1S_RYR1</td>\n",
       "      <td>desflurane</td>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>November 2018</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td></td>\n",
       "      <td>Homozygous for alleles other than HLA-B*15:02</td>\n",
       "      <td>*X/*X b</td>\n",
       "      <td>Non-carrier of HLA-B*15:02.  No HLA-B*15:02 al...</td>\n",
       "      <td>Normal or reduced risk of oxcarbazepine-induce...</td>\n",
       "      <td></td>\n",
       "      <td>Use oxcarbazepine per standard dosing guidelines.</td>\n",
       "      <td></td>\n",
       "      <td>HLA</td>\n",
       "      <td>oxcarbazepine</td>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>December 2017</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td></td>\n",
       "      <td>Heterozygote or homozygous for HLA-B*15:02</td>\n",
       "      <td>*15:02/*X b*15:02/*15:02</td>\n",
       "      <td>Carrier of HLA-B*15:02.  One or two *15:02 all...</td>\n",
       "      <td>Increased risk of oxcarbazepine-induced SJS/TEN</td>\n",
       "      <td></td>\n",
       "      <td>A. If patient is oxcarbazepine-naive, do not u...</td>\n",
       "      <td></td>\n",
       "      <td>HLA</td>\n",
       "      <td>oxcarbazepine</td>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>December 2017</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td></td>\n",
       "      <td>Low function, Homozygous variant or mutant (tw...</td>\n",
       "      <td>*5/*5, *5/*15, *5/*17, *15/*15, *15/*17, *17/*17</td>\n",
       "      <td>CC</td>\n",
       "      <td>High myopathy risk</td>\n",
       "      <td></td>\n",
       "      <td>Prescribe a lower dose or consider an alternat...</td>\n",
       "      <td>Prescribe a lower dose or consider an alternat...</td>\n",
       "      <td>SLCO1B1</td>\n",
       "      <td>simvastatin</td>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>October 2014 Update</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td></td>\n",
       "      <td>Homozygous variant, DPD deficiency (~0.2% of p...</td>\n",
       "      <td>*2A/*2A; *13/*13; rs67376798A c / rs67376798A c</td>\n",
       "      <td>Homozygous variant, DPD deficiency (~0.2% of p...</td>\n",
       "      <td>Complete DPD deficiency and increased risk for...</td>\n",
       "      <td></td>\n",
       "      <td>Select alternate drug</td>\n",
       "      <td>Select alternate drug</td>\n",
       "      <td>DPYD</td>\n",
       "      <td>tegafur</td>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>November 2017 Update on PharmGKB</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td></td>\n",
       "      <td>HLA-B*5701</td>\n",
       "      <td></td>\n",
       "      <td>HLA-B*5701</td>\n",
       "      <td></td>\n",
       "      <td>HLA-B*5701-positive patients have a strongly i...</td>\n",
       "      <td>Abacavir is contra-indicated for HLA-B*5701-po...</td>\n",
       "      <td></td>\n",
       "      <td>HLA</td>\n",
       "      <td>abacavir</td>\n",
       "      <td>DPWG_Guideline</td>\n",
       "      <td>August 2019 Update</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td></td>\n",
       "      <td>HLA-B*5701</td>\n",
       "      <td></td>\n",
       "      <td>HLA-B*5701</td>\n",
       "      <td></td>\n",
       "      <td>HLA-B*5701-positive patients have a strongly i...</td>\n",
       "      <td>Abacavir is contra-indicated for HLA-B*5701-po...</td>\n",
       "      <td></td>\n",
       "      <td>HLA</td>\n",
       "      <td>abacavir</td>\n",
       "      <td>DPWG_Guideline</td>\n",
       "      <td>November 2018 Update</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td></td>\n",
       "      <td>HLA-B*5701</td>\n",
       "      <td></td>\n",
       "      <td>HLA-B*5701</td>\n",
       "      <td></td>\n",
       "      <td>HLA-B*5701-positive patients have an 80-fold e...</td>\n",
       "      <td>1. Regularly monitor the patient’s liver funct...</td>\n",
       "      <td></td>\n",
       "      <td>HLA</td>\n",
       "      <td>flucloxacillin</td>\n",
       "      <td>DPWG_Guideline</td>\n",
       "      <td>November 2018 Guideline</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td></td>\n",
       "      <td>CYP3A5 homozygous expressor</td>\n",
       "      <td></td>\n",
       "      <td>CYP3A5 homozygous expressor</td>\n",
       "      <td></td>\n",
       "      <td>An increase of the initial dose can result in ...</td>\n",
       "      <td>In addition to the patient’s genotype, the met...</td>\n",
       "      <td></td>\n",
       "      <td>CYP3A5</td>\n",
       "      <td>tacrolimus</td>\n",
       "      <td>DPWG_Guideline</td>\n",
       "      <td>May 2020 Update</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td></td>\n",
       "      <td>CYP3A5 homozygous expressor</td>\n",
       "      <td></td>\n",
       "      <td>CYP3A5 homozygous expressor</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>In addition to the patient’s genotype, the met...</td>\n",
       "      <td></td>\n",
       "      <td>CYP3A5</td>\n",
       "      <td>tacrolimus</td>\n",
       "      <td>DPWG_Guideline</td>\n",
       "      <td>November 2018 Update</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   phenotype_category                                          phenotype  \\\n",
       "0                      Very low risk of hypersensitivity (constitutes...   \n",
       "1                        High risk of hypersensitivity (~6% of patients)   \n",
       "2                                Low or reduced risk of allopurinol SCAR   \n",
       "3                       Significantly increased risk of allopurinol SCAR   \n",
       "4                      Homozygous for alleles other than HLA-B*15:02 ...   \n",
       "5                      Heterozygote or homozygous for HLA-A*31:01 and...   \n",
       "6                      Heterozygote or homozygous for HLA-B*15:02 and...   \n",
       "7                                     Malignant Hyperthermia susceptible   \n",
       "8                                               Uncertain susceptibility   \n",
       "9                          Homozygous for alleles other than HLA-B*15:02   \n",
       "10                            Heterozygote or homozygous for HLA-B*15:02   \n",
       "11                     Low function, Homozygous variant or mutant (tw...   \n",
       "12                     Homozygous variant, DPD deficiency (~0.2% of p...   \n",
       "13                                                            HLA-B*5701   \n",
       "14                                                            HLA-B*5701   \n",
       "15                                                            HLA-B*5701   \n",
       "16                                           CYP3A5 homozygous expressor   \n",
       "17                                           CYP3A5 homozygous expressor   \n",
       "\n",
       "                                           diplotype  \\\n",
       "0                                            *X/*X c   \n",
       "1                          *57:01/*X c *57:01/*57:01   \n",
       "2                                            *X/*X a   \n",
       "3                          *58:01/*X a *58:01/*58:01   \n",
       "4                                     *X/*X b*Y/*Y c   \n",
       "5                    *X/*X b*31:01/*Y c*31:01/*31:01   \n",
       "6                           *15:02/*X b*15:02/*15:02   \n",
       "7                                                      \n",
       "8                                                      \n",
       "9                                            *X/*X b   \n",
       "10                          *15:02/*X b*15:02/*15:02   \n",
       "11  *5/*5, *5/*15, *5/*17, *15/*15, *15/*17, *17/*17   \n",
       "12   *2A/*2A; *13/*13; rs67376798A c / rs67376798A c   \n",
       "13                                                     \n",
       "14                                                     \n",
       "15                                                     \n",
       "16                                                     \n",
       "17                                                     \n",
       "\n",
       "                                             genotype  \\\n",
       "0   Absence of *57:01 alleles (reported as \"negati...   \n",
       "1   Presence of at least one *57:01 allele (report...   \n",
       "2   Absence of *58:01 alleles (reported as \"negati...   \n",
       "3   Presence of at least one *58:01 allele (report...   \n",
       "4   Non-carrier of HLA-B*15:02 or HLA-A*31:01.  No...   \n",
       "5   Carrier of HLA-A*31:01.  One or two *31:01 all...   \n",
       "6   Carrier of HLA-B*15:02.  One or two *15:02 all...   \n",
       "7   An individual heterozygousb for a RYR1 or CACN...   \n",
       "8   An individual negative for a RYR1 or CACNA1S m...   \n",
       "9   Non-carrier of HLA-B*15:02.  No HLA-B*15:02 al...   \n",
       "10  Carrier of HLA-B*15:02.  One or two *15:02 all...   \n",
       "11                                                 CC   \n",
       "12  Homozygous variant, DPD deficiency (~0.2% of p...   \n",
       "13                                         HLA-B*5701   \n",
       "14                                         HLA-B*5701   \n",
       "15                                         HLA-B*5701   \n",
       "16                        CYP3A5 homozygous expressor   \n",
       "17                        CYP3A5 homozygous expressor   \n",
       "\n",
       "                                          implication  \\\n",
       "0    Low or reduced risk of abacavir hypersensitivity   \n",
       "1   Significantly increased risk of abacavir hyper...   \n",
       "2             Low or reduced risk of allopurinol SCAR   \n",
       "3    Significantly increased risk of allopurinol SCAR   \n",
       "4   Normal or reduced risk of carbamazepine-induce...   \n",
       "5   Increased risk of carbamazepine-induced SJS/TE...   \n",
       "6     Increased risk of carbamazepine-induced SJS/TEN   \n",
       "7   Individuals are at increased risk of developin...   \n",
       "8   These results do not eliminate the chance that...   \n",
       "9   Normal or reduced risk of oxcarbazepine-induce...   \n",
       "10    Increased risk of oxcarbazepine-induced SJS/TEN   \n",
       "11                                 High myopathy risk   \n",
       "12  Complete DPD deficiency and increased risk for...   \n",
       "13                                                      \n",
       "14                                                      \n",
       "15                                                      \n",
       "16                                                      \n",
       "17                                                      \n",
       "\n",
       "                                          description  \\\n",
       "0                                                       \n",
       "1                                                       \n",
       "2                                                       \n",
       "3                                                       \n",
       "4                                                       \n",
       "5                                                       \n",
       "6                                                       \n",
       "7                                                       \n",
       "8                                                       \n",
       "9                                                       \n",
       "10                                                      \n",
       "11                                                      \n",
       "12                                                      \n",
       "13  HLA-B*5701-positive patients have a strongly i...   \n",
       "14  HLA-B*5701-positive patients have a strongly i...   \n",
       "15  HLA-B*5701-positive patients have an 80-fold e...   \n",
       "16  An increase of the initial dose can result in ...   \n",
       "17                                                      \n",
       "\n",
       "                                       recommendation  \\\n",
       "0         Use abacavir per standard dosing guidelines   \n",
       "1                         Abacavir is not recommended   \n",
       "2      Use allopurinol per standard dosing guidelines   \n",
       "3                      Allopurinol is contraindicated   \n",
       "4   Use carbamazepine per standard dosing guidelin...   \n",
       "5   A. If patient is carbamazepine-naive and alter...   \n",
       "6   A. If patient is carbamazepine-naive, do not u...   \n",
       "7   Halogenated volatile anesthetics or depolarizi...   \n",
       "8   Clinical findings, family history, further gen...   \n",
       "9   Use oxcarbazepine per standard dosing guidelines.   \n",
       "10  A. If patient is oxcarbazepine-naive, do not u...   \n",
       "11  Prescribe a lower dose or consider an alternat...   \n",
       "12                              Select alternate drug   \n",
       "13  Abacavir is contra-indicated for HLA-B*5701-po...   \n",
       "14  Abacavir is contra-indicated for HLA-B*5701-po...   \n",
       "15  1. Regularly monitor the patient’s liver funct...   \n",
       "16  In addition to the patient’s genotype, the met...   \n",
       "17  In addition to the patient’s genotype, the met...   \n",
       "\n",
       "                                               dosing          gene  \\\n",
       "0                                                             HLA_B   \n",
       "1                                                             HLA_B   \n",
       "2                                                             HLA_B   \n",
       "3                                                             HLA_B   \n",
       "4                                                               HLA   \n",
       "5                                                               HLA   \n",
       "6                                                               HLA   \n",
       "7   Halogenated volatile anesthetics or depolarizi...  CACNA1S_RYR1   \n",
       "8   Clinical findings, family history, further gen...  CACNA1S_RYR1   \n",
       "9                                                               HLA   \n",
       "10                                                              HLA   \n",
       "11  Prescribe a lower dose or consider an alternat...       SLCO1B1   \n",
       "12                              Select alternate drug          DPYD   \n",
       "13                                                              HLA   \n",
       "14                                                              HLA   \n",
       "15                                                              HLA   \n",
       "16                                                           CYP3A5   \n",
       "17                                                           CYP3A5   \n",
       "\n",
       "              drug    organization                             title  \\\n",
       "0         abacavir  CPIC_Guideline                   May 2014 Update   \n",
       "1         abacavir  CPIC_Guideline                   May 2014 Update   \n",
       "2      allopurinol  CPIC_Guideline               January 2016 Update   \n",
       "3      allopurinol  CPIC_Guideline               January 2016 Update   \n",
       "4    carbamazepine  CPIC_Guideline                     December 2017   \n",
       "5    carbamazepine  CPIC_Guideline                     December 2017   \n",
       "6    carbamazepine  CPIC_Guideline                     December 2017   \n",
       "7       desflurane  CPIC_Guideline                     November 2018   \n",
       "8       desflurane  CPIC_Guideline                     November 2018   \n",
       "9    oxcarbazepine  CPIC_Guideline                     December 2017   \n",
       "10   oxcarbazepine  CPIC_Guideline                     December 2017   \n",
       "11     simvastatin  CPIC_Guideline               October 2014 Update   \n",
       "12         tegafur  CPIC_Guideline  November 2017 Update on PharmGKB   \n",
       "13        abacavir  DPWG_Guideline                August 2019 Update   \n",
       "14        abacavir  DPWG_Guideline              November 2018 Update   \n",
       "15  flucloxacillin  DPWG_Guideline           November 2018 Guideline   \n",
       "16      tacrolimus  DPWG_Guideline                   May 2020 Update   \n",
       "17      tacrolimus  DPWG_Guideline              November 2018 Update   \n",
       "\n",
       "                                                 link data_source update_date  \\\n",
       "0   https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05   \n",
       "1   https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05   \n",
       "2   https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05   \n",
       "3   https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05   \n",
       "4   https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05   \n",
       "5   https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05   \n",
       "6   https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05   \n",
       "7   https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05   \n",
       "8   https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05   \n",
       "9   https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05   \n",
       "10  https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05   \n",
       "11  https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05   \n",
       "12  https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05   \n",
       "13  https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05   \n",
       "14  https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05   \n",
       "15  https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05   \n",
       "16  https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05   \n",
       "17  https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05   \n",
       "\n",
       "                                              variant  \n",
       "0                                                      \n",
       "1                                                      \n",
       "2                                                      \n",
       "3                                                      \n",
       "4                                                      \n",
       "5                                                      \n",
       "6                                                      \n",
       "7   RYR1 c.103T>C; p.(Cys35Arg), RYR1 c.130C>T; p....  \n",
       "8                                                      \n",
       "9                                                      \n",
       "10                                                     \n",
       "11                                                     \n",
       "12                                                     \n",
       "13                                                     \n",
       "14                                                     \n",
       "15                                                     \n",
       "16                                                     \n",
       "17                                                     "
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_pheno = pd.read_csv(\"processed/phenotype_drug_relation_no_metabolizer.csv\").fillna(\"\")\n",
    "df_pheno"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "id": "98b039fa",
   "metadata": {},
   "outputs": [],
   "source": [
    "haplotype_record_list = []\n",
    "diplotype_record_list = []\n",
    "\n",
    "for index, row in df_pheno.iterrows():\n",
    "    diplotype_list = row[\"diplotype\"].replace(\"a\", \"\").replace(\"b\", \"\").replace(\"c\", \"\").replace(\"d\", \"\").split(\" \")\n",
    "    diplotype_list = list(filter(lambda x: x != \"\" and \"/\" in x  and x != \"/\", [x.replace(\",\", \"\").replace(\";\", \"\").strip() for x in diplotype_list]))\n",
    "    variant_list = list(filter(lambda x: x != \"\", [x.split(\";\")[0].strip() for x in row[\"variant\"].split(\",\")]))\n",
    "    gene = row[\"gene\"].replace(\"_\", \"-\")\n",
    "    for diplo in diplotype_list:\n",
    "        diplotype_record_list.append(\n",
    "            (\"{} {}\".format(gene, diplo), row[\"phenotype_category\"], row[\"phenotype\"], row[\"genotype\"],\n",
    "             row[\"implication\"], row[\"description\"], row[\"recommendation\"], row[\"dosing\"], row[\"drug\"],\n",
    "             row[\"organization\"], row[\"title\"], row[\"link\"], row[\"data_source\"], row[\"update_date\"])\n",
    "        )\n",
    "    for var in variant_list:\n",
    "        haplotype_record_list.append(\n",
    "            (var, row[\"phenotype_category\"], row[\"phenotype\"], row[\"genotype\"],\n",
    "             row[\"implication\"], row[\"description\"], row[\"recommendation\"], row[\"dosing\"], row[\"drug\"],\n",
    "             row[\"organization\"], row[\"title\"], row[\"link\"], row[\"data_source\"], row[\"update_date\"])\n",
    "        )"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "id": "33fffb71",
   "metadata": {},
   "outputs": [],
   "source": [
    "df_haplotype_guideline = pd.DataFrame(\n",
    "    haplotype_record_list,\n",
    "    columns=[\"haplotype\", \"phenotype_category\", \"phenotype\", \"genotype\",\n",
    "             \"implication\", \"description\", \"recommendation\", \"dosing\", \"drug\",\n",
    "             \"organization\", \"title\", \"link\", \"data_source\", \"update_date\"])\n",
    "\n",
    "df_diplotype_guideline = pd.DataFrame(\n",
    "    diplotype_record_list,\n",
    "    columns=[\"diplotype\", \"phenotype_category\", \"phenotype\", \"genotype\",\n",
    "             \"implication\", \"description\", \"recommendation\", \"dosing\", \"drug\",\n",
    "             \"organization\", \"title\", \"link\", \"data_source\", \"update_date\"])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "id": "7ff20300",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>haplotype</th>\n",
       "      <th>phenotype_category</th>\n",
       "      <th>phenotype</th>\n",
       "      <th>genotype</th>\n",
       "      <th>implication</th>\n",
       "      <th>description</th>\n",
       "      <th>recommendation</th>\n",
       "      <th>dosing</th>\n",
       "      <th>drug</th>\n",
       "      <th>organization</th>\n",
       "      <th>title</th>\n",
       "      <th>link</th>\n",
       "      <th>data_source</th>\n",
       "      <th>update_date</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>RYR1 c.103T&gt;C</td>\n",
       "      <td></td>\n",
       "      <td>Malignant Hyperthermia susceptible</td>\n",
       "      <td>An individual heterozygousb for a RYR1 or CACN...</td>\n",
       "      <td>Individuals are at increased risk of developin...</td>\n",
       "      <td></td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>desflurane</td>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>November 2018</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>RYR1 c.130C&gt;T</td>\n",
       "      <td></td>\n",
       "      <td>Malignant Hyperthermia susceptible</td>\n",
       "      <td>An individual heterozygousb for a RYR1 or CACN...</td>\n",
       "      <td>Individuals are at increased risk of developin...</td>\n",
       "      <td></td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>desflurane</td>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>November 2018</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>RYR1 c.487C&gt;T</td>\n",
       "      <td></td>\n",
       "      <td>Malignant Hyperthermia susceptible</td>\n",
       "      <td>An individual heterozygousb for a RYR1 or CACN...</td>\n",
       "      <td>Individuals are at increased risk of developin...</td>\n",
       "      <td></td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>desflurane</td>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>November 2018</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>RYR1 c.488G&gt;T</td>\n",
       "      <td></td>\n",
       "      <td>Malignant Hyperthermia susceptible</td>\n",
       "      <td>An individual heterozygousb for a RYR1 or CACN...</td>\n",
       "      <td>Individuals are at increased risk of developin...</td>\n",
       "      <td></td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>desflurane</td>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>November 2018</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>RYR1 c.742G&gt;A/C</td>\n",
       "      <td></td>\n",
       "      <td>Malignant Hyperthermia susceptible</td>\n",
       "      <td>An individual heterozygousb for a RYR1 or CACN...</td>\n",
       "      <td>Individuals are at increased risk of developin...</td>\n",
       "      <td></td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>desflurane</td>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>November 2018</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>RYR1 c.982C&gt;T</td>\n",
       "      <td></td>\n",
       "      <td>Malignant Hyperthermia susceptible</td>\n",
       "      <td>An individual heterozygousb for a RYR1 or CACN...</td>\n",
       "      <td>Individuals are at increased risk of developin...</td>\n",
       "      <td></td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>desflurane</td>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>November 2018</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>RYR1 c.1021G&gt;C</td>\n",
       "      <td></td>\n",
       "      <td>Malignant Hyperthermia susceptible</td>\n",
       "      <td>An individual heterozygousb for a RYR1 or CACN...</td>\n",
       "      <td>Individuals are at increased risk of developin...</td>\n",
       "      <td></td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>desflurane</td>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>November 2018</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>RYR1 c.1021G&gt;A</td>\n",
       "      <td></td>\n",
       "      <td>Malignant Hyperthermia susceptible</td>\n",
       "      <td>An individual heterozygousb for a RYR1 or CACN...</td>\n",
       "      <td>Individuals are at increased risk of developin...</td>\n",
       "      <td></td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>desflurane</td>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>November 2018</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>RYR1 c.1201C&gt;T</td>\n",
       "      <td></td>\n",
       "      <td>Malignant Hyperthermia susceptible</td>\n",
       "      <td>An individual heterozygousb for a RYR1 or CACN...</td>\n",
       "      <td>Individuals are at increased risk of developin...</td>\n",
       "      <td></td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>desflurane</td>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>November 2018</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>RYR1 c.1209C&gt;G</td>\n",
       "      <td></td>\n",
       "      <td>Malignant Hyperthermia susceptible</td>\n",
       "      <td>An individual heterozygousb for a RYR1 or CACN...</td>\n",
       "      <td>Individuals are at increased risk of developin...</td>\n",
       "      <td></td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>desflurane</td>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>November 2018</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>RYR1 c.1565A&gt;C</td>\n",
       "      <td></td>\n",
       "      <td>Malignant Hyperthermia susceptible</td>\n",
       "      <td>An individual heterozygousb for a RYR1 or CACN...</td>\n",
       "      <td>Individuals are at increased risk of developin...</td>\n",
       "      <td></td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>desflurane</td>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>November 2018</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>RYR1 c.1589G&gt;A</td>\n",
       "      <td></td>\n",
       "      <td>Malignant Hyperthermia susceptible</td>\n",
       "      <td>An individual heterozygousb for a RYR1 or CACN...</td>\n",
       "      <td>Individuals are at increased risk of developin...</td>\n",
       "      <td></td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>desflurane</td>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>November 2018</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>RYR1 c.1597C&gt;T</td>\n",
       "      <td></td>\n",
       "      <td>Malignant Hyperthermia susceptible</td>\n",
       "      <td>An individual heterozygousb for a RYR1 or CACN...</td>\n",
       "      <td>Individuals are at increased risk of developin...</td>\n",
       "      <td></td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>desflurane</td>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>November 2018</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>RYR1 c.1598G&gt;A</td>\n",
       "      <td></td>\n",
       "      <td>Malignant Hyperthermia susceptible</td>\n",
       "      <td>An individual heterozygousb for a RYR1 or CACN...</td>\n",
       "      <td>Individuals are at increased risk of developin...</td>\n",
       "      <td></td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>desflurane</td>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>November 2018</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>RYR1 c.1654C&gt;T</td>\n",
       "      <td></td>\n",
       "      <td>Malignant Hyperthermia susceptible</td>\n",
       "      <td>An individual heterozygousb for a RYR1 or CACN...</td>\n",
       "      <td>Individuals are at increased risk of developin...</td>\n",
       "      <td></td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>desflurane</td>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>November 2018</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>RYR1 c.1840C&gt;T</td>\n",
       "      <td></td>\n",
       "      <td>Malignant Hyperthermia susceptible</td>\n",
       "      <td>An individual heterozygousb for a RYR1 or CACN...</td>\n",
       "      <td>Individuals are at increased risk of developin...</td>\n",
       "      <td></td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>desflurane</td>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>November 2018</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>RYR1 c.1841G&gt;T</td>\n",
       "      <td></td>\n",
       "      <td>Malignant Hyperthermia susceptible</td>\n",
       "      <td>An individual heterozygousb for a RYR1 or CACN...</td>\n",
       "      <td>Individuals are at increased risk of developin...</td>\n",
       "      <td></td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>desflurane</td>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>November 2018</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>RYR1 c.6487C&gt;T</td>\n",
       "      <td></td>\n",
       "      <td>Malignant Hyperthermia susceptible</td>\n",
       "      <td>An individual heterozygousb for a RYR1 or CACN...</td>\n",
       "      <td>Individuals are at increased risk of developin...</td>\n",
       "      <td></td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>desflurane</td>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>November 2018</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>RYR1 c.6488G&gt;A</td>\n",
       "      <td></td>\n",
       "      <td>Malignant Hyperthermia susceptible</td>\n",
       "      <td>An individual heterozygousb for a RYR1 or CACN...</td>\n",
       "      <td>Individuals are at increased risk of developin...</td>\n",
       "      <td></td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>desflurane</td>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>November 2018</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>RYR1 c.6502G&gt;A</td>\n",
       "      <td></td>\n",
       "      <td>Malignant Hyperthermia susceptible</td>\n",
       "      <td>An individual heterozygousb for a RYR1 or CACN...</td>\n",
       "      <td>Individuals are at increased risk of developin...</td>\n",
       "      <td></td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>desflurane</td>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>November 2018</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>RYR1 c.6617C&gt;G</td>\n",
       "      <td></td>\n",
       "      <td>Malignant Hyperthermia susceptible</td>\n",
       "      <td>An individual heterozygousb for a RYR1 or CACN...</td>\n",
       "      <td>Individuals are at increased risk of developin...</td>\n",
       "      <td></td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>desflurane</td>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>November 2018</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>RYR1 c.6617C&gt;T</td>\n",
       "      <td></td>\n",
       "      <td>Malignant Hyperthermia susceptible</td>\n",
       "      <td>An individual heterozygousb for a RYR1 or CACN...</td>\n",
       "      <td>Individuals are at increased risk of developin...</td>\n",
       "      <td></td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>desflurane</td>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>November 2018</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>RYR1 c.7007G&gt;A</td>\n",
       "      <td></td>\n",
       "      <td>Malignant Hyperthermia susceptible</td>\n",
       "      <td>An individual heterozygousb for a RYR1 or CACN...</td>\n",
       "      <td>Individuals are at increased risk of developin...</td>\n",
       "      <td></td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>desflurane</td>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>November 2018</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>RYR1 c.7039_7041delGAG/RYR1 c.7042_7044delGAG</td>\n",
       "      <td></td>\n",
       "      <td>Malignant Hyperthermia susceptible</td>\n",
       "      <td>An individual heterozygousb for a RYR1 or CACN...</td>\n",
       "      <td>Individuals are at increased risk of developin...</td>\n",
       "      <td></td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>desflurane</td>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>November 2018</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>RYR1 c.7048G&gt;A</td>\n",
       "      <td></td>\n",
       "      <td>Malignant Hyperthermia susceptible</td>\n",
       "      <td>An individual heterozygousb for a RYR1 or CACN...</td>\n",
       "      <td>Individuals are at increased risk of developin...</td>\n",
       "      <td></td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>desflurane</td>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>November 2018</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>RYR1 c.7063C&gt;T</td>\n",
       "      <td></td>\n",
       "      <td>Malignant Hyperthermia susceptible</td>\n",
       "      <td>An individual heterozygousb for a RYR1 or CACN...</td>\n",
       "      <td>Individuals are at increased risk of developin...</td>\n",
       "      <td></td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>desflurane</td>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>November 2018</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>RYR1 c.7124G&gt;C</td>\n",
       "      <td></td>\n",
       "      <td>Malignant Hyperthermia susceptible</td>\n",
       "      <td>An individual heterozygousb for a RYR1 or CACN...</td>\n",
       "      <td>Individuals are at increased risk of developin...</td>\n",
       "      <td></td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>desflurane</td>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>November 2018</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>RYR1 c.7282G&gt;A</td>\n",
       "      <td></td>\n",
       "      <td>Malignant Hyperthermia susceptible</td>\n",
       "      <td>An individual heterozygousb for a RYR1 or CACN...</td>\n",
       "      <td>Individuals are at increased risk of developin...</td>\n",
       "      <td></td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>desflurane</td>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>November 2018</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>RYR1 c.7300G&gt;A</td>\n",
       "      <td></td>\n",
       "      <td>Malignant Hyperthermia susceptible</td>\n",
       "      <td>An individual heterozygousb for a RYR1 or CACN...</td>\n",
       "      <td>Individuals are at increased risk of developin...</td>\n",
       "      <td></td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>desflurane</td>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>November 2018</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>RYR1 c.7304G&gt;A</td>\n",
       "      <td></td>\n",
       "      <td>Malignant Hyperthermia susceptible</td>\n",
       "      <td>An individual heterozygousb for a RYR1 or CACN...</td>\n",
       "      <td>Individuals are at increased risk of developin...</td>\n",
       "      <td></td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>desflurane</td>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>November 2018</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>RYR1 c.7354C&gt;T</td>\n",
       "      <td></td>\n",
       "      <td>Malignant Hyperthermia susceptible</td>\n",
       "      <td>An individual heterozygousb for a RYR1 or CACN...</td>\n",
       "      <td>Individuals are at increased risk of developin...</td>\n",
       "      <td></td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>desflurane</td>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>November 2018</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>RYR1 c.7360C&gt;T</td>\n",
       "      <td></td>\n",
       "      <td>Malignant Hyperthermia susceptible</td>\n",
       "      <td>An individual heterozygousb for a RYR1 or CACN...</td>\n",
       "      <td>Individuals are at increased risk of developin...</td>\n",
       "      <td></td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>desflurane</td>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>November 2018</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>RYR1 c.7361G&gt;A</td>\n",
       "      <td></td>\n",
       "      <td>Malignant Hyperthermia susceptible</td>\n",
       "      <td>An individual heterozygousb for a RYR1 or CACN...</td>\n",
       "      <td>Individuals are at increased risk of developin...</td>\n",
       "      <td></td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>desflurane</td>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>November 2018</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>RYR1 c.7372C&gt;T</td>\n",
       "      <td></td>\n",
       "      <td>Malignant Hyperthermia susceptible</td>\n",
       "      <td>An individual heterozygousb for a RYR1 or CACN...</td>\n",
       "      <td>Individuals are at increased risk of developin...</td>\n",
       "      <td></td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>desflurane</td>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>November 2018</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34</th>\n",
       "      <td>RYR1 c.7373G&gt;A</td>\n",
       "      <td></td>\n",
       "      <td>Malignant Hyperthermia susceptible</td>\n",
       "      <td>An individual heterozygousb for a RYR1 or CACN...</td>\n",
       "      <td>Individuals are at increased risk of developin...</td>\n",
       "      <td></td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>desflurane</td>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>November 2018</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35</th>\n",
       "      <td>RYR1 c.7522C&gt;G</td>\n",
       "      <td></td>\n",
       "      <td>Malignant Hyperthermia susceptible</td>\n",
       "      <td>An individual heterozygousb for a RYR1 or CACN...</td>\n",
       "      <td>Individuals are at increased risk of developin...</td>\n",
       "      <td></td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>desflurane</td>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>November 2018</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>36</th>\n",
       "      <td>RYR1 c.7522C&gt;T</td>\n",
       "      <td></td>\n",
       "      <td>Malignant Hyperthermia susceptible</td>\n",
       "      <td>An individual heterozygousb for a RYR1 or CACN...</td>\n",
       "      <td>Individuals are at increased risk of developin...</td>\n",
       "      <td></td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>desflurane</td>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>November 2018</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>37</th>\n",
       "      <td>RYR1 c.7523G&gt;A</td>\n",
       "      <td></td>\n",
       "      <td>Malignant Hyperthermia susceptible</td>\n",
       "      <td>An individual heterozygousb for a RYR1 or CACN...</td>\n",
       "      <td>Individuals are at increased risk of developin...</td>\n",
       "      <td></td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>desflurane</td>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>November 2018</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>38</th>\n",
       "      <td>RYR1 c.9310G&gt;A</td>\n",
       "      <td></td>\n",
       "      <td>Malignant Hyperthermia susceptible</td>\n",
       "      <td>An individual heterozygousb for a RYR1 or CACN...</td>\n",
       "      <td>Individuals are at increased risk of developin...</td>\n",
       "      <td></td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>desflurane</td>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>November 2018</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>39</th>\n",
       "      <td>RYR1 c.11969G&gt;T</td>\n",
       "      <td></td>\n",
       "      <td>Malignant Hyperthermia susceptible</td>\n",
       "      <td>An individual heterozygousb for a RYR1 or CACN...</td>\n",
       "      <td>Individuals are at increased risk of developin...</td>\n",
       "      <td></td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>desflurane</td>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>November 2018</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>40</th>\n",
       "      <td>RYR1 c.14387A&gt;G</td>\n",
       "      <td></td>\n",
       "      <td>Malignant Hyperthermia susceptible</td>\n",
       "      <td>An individual heterozygousb for a RYR1 or CACN...</td>\n",
       "      <td>Individuals are at increased risk of developin...</td>\n",
       "      <td></td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>desflurane</td>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>November 2018</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>41</th>\n",
       "      <td>RYR1 c.14477C&gt;T</td>\n",
       "      <td></td>\n",
       "      <td>Malignant Hyperthermia susceptible</td>\n",
       "      <td>An individual heterozygousb for a RYR1 or CACN...</td>\n",
       "      <td>Individuals are at increased risk of developin...</td>\n",
       "      <td></td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>desflurane</td>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>November 2018</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>42</th>\n",
       "      <td>RYR1 c.14497C&gt;T</td>\n",
       "      <td></td>\n",
       "      <td>Malignant Hyperthermia susceptible</td>\n",
       "      <td>An individual heterozygousb for a RYR1 or CACN...</td>\n",
       "      <td>Individuals are at increased risk of developin...</td>\n",
       "      <td></td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>desflurane</td>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>November 2018</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>43</th>\n",
       "      <td>RYR1 c.14512C&gt;G</td>\n",
       "      <td></td>\n",
       "      <td>Malignant Hyperthermia susceptible</td>\n",
       "      <td>An individual heterozygousb for a RYR1 or CACN...</td>\n",
       "      <td>Individuals are at increased risk of developin...</td>\n",
       "      <td></td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>desflurane</td>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>November 2018</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>44</th>\n",
       "      <td>RYR1 c.14545G&gt;A</td>\n",
       "      <td></td>\n",
       "      <td>Malignant Hyperthermia susceptible</td>\n",
       "      <td>An individual heterozygousb for a RYR1 or CACN...</td>\n",
       "      <td>Individuals are at increased risk of developin...</td>\n",
       "      <td></td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>desflurane</td>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>November 2018</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>45</th>\n",
       "      <td>RYR1 c.14582G&gt;A</td>\n",
       "      <td></td>\n",
       "      <td>Malignant Hyperthermia susceptible</td>\n",
       "      <td>An individual heterozygousb for a RYR1 or CACN...</td>\n",
       "      <td>Individuals are at increased risk of developin...</td>\n",
       "      <td></td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>desflurane</td>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>November 2018</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>46</th>\n",
       "      <td>RYR1 c.14693T&gt;C</td>\n",
       "      <td></td>\n",
       "      <td>Malignant Hyperthermia susceptible</td>\n",
       "      <td>An individual heterozygousb for a RYR1 or CACN...</td>\n",
       "      <td>Individuals are at increased risk of developin...</td>\n",
       "      <td></td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>desflurane</td>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>November 2018</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>47</th>\n",
       "      <td>CACNA1S c.520C&gt;T</td>\n",
       "      <td></td>\n",
       "      <td>Malignant Hyperthermia susceptible</td>\n",
       "      <td>An individual heterozygousb for a RYR1 or CACN...</td>\n",
       "      <td>Individuals are at increased risk of developin...</td>\n",
       "      <td></td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>desflurane</td>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>November 2018</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>48</th>\n",
       "      <td>CACNA1S c3257G&gt;A</td>\n",
       "      <td></td>\n",
       "      <td>Malignant Hyperthermia susceptible</td>\n",
       "      <td>An individual heterozygousb for a RYR1 or CACN...</td>\n",
       "      <td>Individuals are at increased risk of developin...</td>\n",
       "      <td></td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>Halogenated volatile anesthetics or depolarizi...</td>\n",
       "      <td>desflurane</td>\n",
       "      <td>CPIC_Guideline</td>\n",
       "      <td>November 2018</td>\n",
       "      <td>https://pharmgkb.org/guidelineAnnotation/PA166...</td>\n",
       "      <td>guildeline</td>\n",
       "      <td>2021-10-05</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                        haplotype phenotype_category  \\\n",
       "0                                   RYR1 c.103T>C                      \n",
       "1                                   RYR1 c.130C>T                      \n",
       "2                                   RYR1 c.487C>T                      \n",
       "3                                   RYR1 c.488G>T                      \n",
       "4                                 RYR1 c.742G>A/C                      \n",
       "5                                   RYR1 c.982C>T                      \n",
       "6                                  RYR1 c.1021G>C                      \n",
       "7                                  RYR1 c.1021G>A                      \n",
       "8                                  RYR1 c.1201C>T                      \n",
       "9                                  RYR1 c.1209C>G                      \n",
       "10                                 RYR1 c.1565A>C                      \n",
       "11                                 RYR1 c.1589G>A                      \n",
       "12                                 RYR1 c.1597C>T                      \n",
       "13                                 RYR1 c.1598G>A                      \n",
       "14                                 RYR1 c.1654C>T                      \n",
       "15                                 RYR1 c.1840C>T                      \n",
       "16                                 RYR1 c.1841G>T                      \n",
       "17                                 RYR1 c.6487C>T                      \n",
       "18                                 RYR1 c.6488G>A                      \n",
       "19                                 RYR1 c.6502G>A                      \n",
       "20                                 RYR1 c.6617C>G                      \n",
       "21                                 RYR1 c.6617C>T                      \n",
       "22                                 RYR1 c.7007G>A                      \n",
       "23  RYR1 c.7039_7041delGAG/RYR1 c.7042_7044delGAG                      \n",
       "24                                 RYR1 c.7048G>A                      \n",
       "25                                 RYR1 c.7063C>T                      \n",
       "26                                 RYR1 c.7124G>C                      \n",
       "27                                 RYR1 c.7282G>A                      \n",
       "28                                 RYR1 c.7300G>A                      \n",
       "29                                 RYR1 c.7304G>A                      \n",
       "30                                 RYR1 c.7354C>T                      \n",
       "31                                 RYR1 c.7360C>T                      \n",
       "32                                 RYR1 c.7361G>A                      \n",
       "33                                 RYR1 c.7372C>T                      \n",
       "34                                 RYR1 c.7373G>A                      \n",
       "35                                 RYR1 c.7522C>G                      \n",
       "36                                 RYR1 c.7522C>T                      \n",
       "37                                 RYR1 c.7523G>A                      \n",
       "38                                 RYR1 c.9310G>A                      \n",
       "39                                RYR1 c.11969G>T                      \n",
       "40                                RYR1 c.14387A>G                      \n",
       "41                                RYR1 c.14477C>T                      \n",
       "42                                RYR1 c.14497C>T                      \n",
       "43                                RYR1 c.14512C>G                      \n",
       "44                                RYR1 c.14545G>A                      \n",
       "45                                RYR1 c.14582G>A                      \n",
       "46                                RYR1 c.14693T>C                      \n",
       "47                               CACNA1S c.520C>T                      \n",
       "48                               CACNA1S c3257G>A                      \n",
       "\n",
       "                             phenotype  \\\n",
       "0   Malignant Hyperthermia susceptible   \n",
       "1   Malignant Hyperthermia susceptible   \n",
       "2   Malignant Hyperthermia susceptible   \n",
       "3   Malignant Hyperthermia susceptible   \n",
       "4   Malignant Hyperthermia susceptible   \n",
       "5   Malignant Hyperthermia susceptible   \n",
       "6   Malignant Hyperthermia susceptible   \n",
       "7   Malignant Hyperthermia susceptible   \n",
       "8   Malignant Hyperthermia susceptible   \n",
       "9   Malignant Hyperthermia susceptible   \n",
       "10  Malignant Hyperthermia susceptible   \n",
       "11  Malignant Hyperthermia susceptible   \n",
       "12  Malignant Hyperthermia susceptible   \n",
       "13  Malignant Hyperthermia susceptible   \n",
       "14  Malignant Hyperthermia susceptible   \n",
       "15  Malignant Hyperthermia susceptible   \n",
       "16  Malignant Hyperthermia susceptible   \n",
       "17  Malignant Hyperthermia susceptible   \n",
       "18  Malignant Hyperthermia susceptible   \n",
       "19  Malignant Hyperthermia susceptible   \n",
       "20  Malignant Hyperthermia susceptible   \n",
       "21  Malignant Hyperthermia susceptible   \n",
       "22  Malignant Hyperthermia susceptible   \n",
       "23  Malignant Hyperthermia susceptible   \n",
       "24  Malignant Hyperthermia susceptible   \n",
       "25  Malignant Hyperthermia susceptible   \n",
       "26  Malignant Hyperthermia susceptible   \n",
       "27  Malignant Hyperthermia susceptible   \n",
       "28  Malignant Hyperthermia susceptible   \n",
       "29  Malignant Hyperthermia susceptible   \n",
       "30  Malignant Hyperthermia susceptible   \n",
       "31  Malignant Hyperthermia susceptible   \n",
       "32  Malignant Hyperthermia susceptible   \n",
       "33  Malignant Hyperthermia susceptible   \n",
       "34  Malignant Hyperthermia susceptible   \n",
       "35  Malignant Hyperthermia susceptible   \n",
       "36  Malignant Hyperthermia susceptible   \n",
       "37  Malignant Hyperthermia susceptible   \n",
       "38  Malignant Hyperthermia susceptible   \n",
       "39  Malignant Hyperthermia susceptible   \n",
       "40  Malignant Hyperthermia susceptible   \n",
       "41  Malignant Hyperthermia susceptible   \n",
       "42  Malignant Hyperthermia susceptible   \n",
       "43  Malignant Hyperthermia susceptible   \n",
       "44  Malignant Hyperthermia susceptible   \n",
       "45  Malignant Hyperthermia susceptible   \n",
       "46  Malignant Hyperthermia susceptible   \n",
       "47  Malignant Hyperthermia susceptible   \n",
       "48  Malignant Hyperthermia susceptible   \n",
       "\n",
       "                                             genotype  \\\n",
       "0   An individual heterozygousb for a RYR1 or CACN...   \n",
       "1   An individual heterozygousb for a RYR1 or CACN...   \n",
       "2   An individual heterozygousb for a RYR1 or CACN...   \n",
       "3   An individual heterozygousb for a RYR1 or CACN...   \n",
       "4   An individual heterozygousb for a RYR1 or CACN...   \n",
       "5   An individual heterozygousb for a RYR1 or CACN...   \n",
       "6   An individual heterozygousb for a RYR1 or CACN...   \n",
       "7   An individual heterozygousb for a RYR1 or CACN...   \n",
       "8   An individual heterozygousb for a RYR1 or CACN...   \n",
       "9   An individual heterozygousb for a RYR1 or CACN...   \n",
       "10  An individual heterozygousb for a RYR1 or CACN...   \n",
       "11  An individual heterozygousb for a RYR1 or CACN...   \n",
       "12  An individual heterozygousb for a RYR1 or CACN...   \n",
       "13  An individual heterozygousb for a RYR1 or CACN...   \n",
       "14  An individual heterozygousb for a RYR1 or CACN...   \n",
       "15  An individual heterozygousb for a RYR1 or CACN...   \n",
       "16  An individual heterozygousb for a RYR1 or CACN...   \n",
       "17  An individual heterozygousb for a RYR1 or CACN...   \n",
       "18  An individual heterozygousb for a RYR1 or CACN...   \n",
       "19  An individual heterozygousb for a RYR1 or CACN...   \n",
       "20  An individual heterozygousb for a RYR1 or CACN...   \n",
       "21  An individual heterozygousb for a RYR1 or CACN...   \n",
       "22  An individual heterozygousb for a RYR1 or CACN...   \n",
       "23  An individual heterozygousb for a RYR1 or CACN...   \n",
       "24  An individual heterozygousb for a RYR1 or CACN...   \n",
       "25  An individual heterozygousb for a RYR1 or CACN...   \n",
       "26  An individual heterozygousb for a RYR1 or CACN...   \n",
       "27  An individual heterozygousb for a RYR1 or CACN...   \n",
       "28  An individual heterozygousb for a RYR1 or CACN...   \n",
       "29  An individual heterozygousb for a RYR1 or CACN...   \n",
       "30  An individual heterozygousb for a RYR1 or CACN...   \n",
       "31  An individual heterozygousb for a RYR1 or CACN...   \n",
       "32  An individual heterozygousb for a RYR1 or CACN...   \n",
       "33  An individual heterozygousb for a RYR1 or CACN...   \n",
       "34  An individual heterozygousb for a RYR1 or CACN...   \n",
       "35  An individual heterozygousb for a RYR1 or CACN...   \n",
       "36  An individual heterozygousb for a RYR1 or CACN...   \n",
       "37  An individual heterozygousb for a RYR1 or CACN...   \n",
       "38  An individual heterozygousb for a RYR1 or CACN...   \n",
       "39  An individual heterozygousb for a RYR1 or CACN...   \n",
       "40  An individual heterozygousb for a RYR1 or CACN...   \n",
       "41  An individual heterozygousb for a RYR1 or CACN...   \n",
       "42  An individual heterozygousb for a RYR1 or CACN...   \n",
       "43  An individual heterozygousb for a RYR1 or CACN...   \n",
       "44  An individual heterozygousb for a RYR1 or CACN...   \n",
       "45  An individual heterozygousb for a RYR1 or CACN...   \n",
       "46  An individual heterozygousb for a RYR1 or CACN...   \n",
       "47  An individual heterozygousb for a RYR1 or CACN...   \n",
       "48  An individual heterozygousb for a RYR1 or CACN...   \n",
       "\n",
       "                                          implication description  \\\n",
       "0   Individuals are at increased risk of developin...               \n",
       "1   Individuals are at increased risk of developin...               \n",
       "2   Individuals are at increased risk of developin...               \n",
       "3   Individuals are at increased risk of developin...               \n",
       "4   Individuals are at increased risk of developin...               \n",
       "5   Individuals are at increased risk of developin...               \n",
       "6   Individuals are at increased risk of developin...               \n",
       "7   Individuals are at increased risk of developin...               \n",
       "8   Individuals are at increased risk of developin...               \n",
       "9   Individuals are at increased risk of developin...               \n",
       "10  Individuals are at increased risk of developin...               \n",
       "11  Individuals are at increased risk of developin...               \n",
       "12  Individuals are at increased risk of developin...               \n",
       "13  Individuals are at increased risk of developin...               \n",
       "14  Individuals are at increased risk of developin...               \n",
       "15  Individuals are at increased risk of developin...               \n",
       "16  Individuals are at increased risk of developin...               \n",
       "17  Individuals are at increased risk of developin...               \n",
       "18  Individuals are at increased risk of developin...               \n",
       "19  Individuals are at increased risk of developin...               \n",
       "20  Individuals are at increased risk of developin...               \n",
       "21  Individuals are at increased risk of developin...               \n",
       "22  Individuals are at increased risk of developin...               \n",
       "23  Individuals are at increased risk of developin...               \n",
       "24  Individuals are at increased risk of developin...               \n",
       "25  Individuals are at increased risk of developin...               \n",
       "26  Individuals are at increased risk of developin...               \n",
       "27  Individuals are at increased risk of developin...               \n",
       "28  Individuals are at increased risk of developin...               \n",
       "29  Individuals are at increased risk of developin...               \n",
       "30  Individuals are at increased risk of developin...               \n",
       "31  Individuals are at increased risk of developin...               \n",
       "32  Individuals are at increased risk of developin...               \n",
       "33  Individuals are at increased risk of developin...               \n",
       "34  Individuals are at increased risk of developin...               \n",
       "35  Individuals are at increased risk of developin...               \n",
       "36  Individuals are at increased risk of developin...               \n",
       "37  Individuals are at increased risk of developin...               \n",
       "38  Individuals are at increased risk of developin...               \n",
       "39  Individuals are at increased risk of developin...               \n",
       "40  Individuals are at increased risk of developin...               \n",
       "41  Individuals are at increased risk of developin...               \n",
       "42  Individuals are at increased risk of developin...               \n",
       "43  Individuals are at increased risk of developin...               \n",
       "44  Individuals are at increased risk of developin...               \n",
       "45  Individuals are at increased risk of developin...               \n",
       "46  Individuals are at increased risk of developin...               \n",
       "47  Individuals are at increased risk of developin...               \n",
       "48  Individuals are at increased risk of developin...               \n",
       "\n",
       "                                       recommendation  \\\n",
       "0   Halogenated volatile anesthetics or depolarizi...   \n",
       "1   Halogenated volatile anesthetics or depolarizi...   \n",
       "2   Halogenated volatile anesthetics or depolarizi...   \n",
       "3   Halogenated volatile anesthetics or depolarizi...   \n",
       "4   Halogenated volatile anesthetics or depolarizi...   \n",
       "5   Halogenated volatile anesthetics or depolarizi...   \n",
       "6   Halogenated volatile anesthetics or depolarizi...   \n",
       "7   Halogenated volatile anesthetics or depolarizi...   \n",
       "8   Halogenated volatile anesthetics or depolarizi...   \n",
       "9   Halogenated volatile anesthetics or depolarizi...   \n",
       "10  Halogenated volatile anesthetics or depolarizi...   \n",
       "11  Halogenated volatile anesthetics or depolarizi...   \n",
       "12  Halogenated volatile anesthetics or depolarizi...   \n",
       "13  Halogenated volatile anesthetics or depolarizi...   \n",
       "14  Halogenated volatile anesthetics or depolarizi...   \n",
       "15  Halogenated volatile anesthetics or depolarizi...   \n",
       "16  Halogenated volatile anesthetics or depolarizi...   \n",
       "17  Halogenated volatile anesthetics or depolarizi...   \n",
       "18  Halogenated volatile anesthetics or depolarizi...   \n",
       "19  Halogenated volatile anesthetics or depolarizi...   \n",
       "20  Halogenated volatile anesthetics or depolarizi...   \n",
       "21  Halogenated volatile anesthetics or depolarizi...   \n",
       "22  Halogenated volatile anesthetics or depolarizi...   \n",
       "23  Halogenated volatile anesthetics or depolarizi...   \n",
       "24  Halogenated volatile anesthetics or depolarizi...   \n",
       "25  Halogenated volatile anesthetics or depolarizi...   \n",
       "26  Halogenated volatile anesthetics or depolarizi...   \n",
       "27  Halogenated volatile anesthetics or depolarizi...   \n",
       "28  Halogenated volatile anesthetics or depolarizi...   \n",
       "29  Halogenated volatile anesthetics or depolarizi...   \n",
       "30  Halogenated volatile anesthetics or depolarizi...   \n",
       "31  Halogenated volatile anesthetics or depolarizi...   \n",
       "32  Halogenated volatile anesthetics or depolarizi...   \n",
       "33  Halogenated volatile anesthetics or depolarizi...   \n",
       "34  Halogenated volatile anesthetics or depolarizi...   \n",
       "35  Halogenated volatile anesthetics or depolarizi...   \n",
       "36  Halogenated volatile anesthetics or depolarizi...   \n",
       "37  Halogenated volatile anesthetics or depolarizi...   \n",
       "38  Halogenated volatile anesthetics or depolarizi...   \n",
       "39  Halogenated volatile anesthetics or depolarizi...   \n",
       "40  Halogenated volatile anesthetics or depolarizi...   \n",
       "41  Halogenated volatile anesthetics or depolarizi...   \n",
       "42  Halogenated volatile anesthetics or depolarizi...   \n",
       "43  Halogenated volatile anesthetics or depolarizi...   \n",
       "44  Halogenated volatile anesthetics or depolarizi...   \n",
       "45  Halogenated volatile anesthetics or depolarizi...   \n",
       "46  Halogenated volatile anesthetics or depolarizi...   \n",
       "47  Halogenated volatile anesthetics or depolarizi...   \n",
       "48  Halogenated volatile anesthetics or depolarizi...   \n",
       "\n",
       "                                               dosing        drug  \\\n",
       "0   Halogenated volatile anesthetics or depolarizi...  desflurane   \n",
       "1   Halogenated volatile anesthetics or depolarizi...  desflurane   \n",
       "2   Halogenated volatile anesthetics or depolarizi...  desflurane   \n",
       "3   Halogenated volatile anesthetics or depolarizi...  desflurane   \n",
       "4   Halogenated volatile anesthetics or depolarizi...  desflurane   \n",
       "5   Halogenated volatile anesthetics or depolarizi...  desflurane   \n",
       "6   Halogenated volatile anesthetics or depolarizi...  desflurane   \n",
       "7   Halogenated volatile anesthetics or depolarizi...  desflurane   \n",
       "8   Halogenated volatile anesthetics or depolarizi...  desflurane   \n",
       "9   Halogenated volatile anesthetics or depolarizi...  desflurane   \n",
       "10  Halogenated volatile anesthetics or depolarizi...  desflurane   \n",
       "11  Halogenated volatile anesthetics or depolarizi...  desflurane   \n",
       "12  Halogenated volatile anesthetics or depolarizi...  desflurane   \n",
       "13  Halogenated volatile anesthetics or depolarizi...  desflurane   \n",
       "14  Halogenated volatile anesthetics or depolarizi...  desflurane   \n",
       "15  Halogenated volatile anesthetics or depolarizi...  desflurane   \n",
       "16  Halogenated volatile anesthetics or depolarizi...  desflurane   \n",
       "17  Halogenated volatile anesthetics or depolarizi...  desflurane   \n",
       "18  Halogenated volatile anesthetics or depolarizi...  desflurane   \n",
       "19  Halogenated volatile anesthetics or depolarizi...  desflurane   \n",
       "20  Halogenated volatile anesthetics or depolarizi...  desflurane   \n",
       "21  Halogenated volatile anesthetics or depolarizi...  desflurane   \n",
       "22  Halogenated volatile anesthetics or depolarizi...  desflurane   \n",
       "23  Halogenated volatile anesthetics or depolarizi...  desflurane   \n",
       "24  Halogenated volatile anesthetics or depolarizi...  desflurane   \n",
       "25  Halogenated volatile anesthetics or depolarizi...  desflurane   \n",
       "26  Halogenated volatile anesthetics or depolarizi...  desflurane   \n",
       "27  Halogenated volatile anesthetics or depolarizi...  desflurane   \n",
       "28  Halogenated volatile anesthetics or depolarizi...  desflurane   \n",
       "29  Halogenated volatile anesthetics or depolarizi...  desflurane   \n",
       "30  Halogenated volatile anesthetics or depolarizi...  desflurane   \n",
       "31  Halogenated volatile anesthetics or depolarizi...  desflurane   \n",
       "32  Halogenated volatile anesthetics or depolarizi...  desflurane   \n",
       "33  Halogenated volatile anesthetics or depolarizi...  desflurane   \n",
       "34  Halogenated volatile anesthetics or depolarizi...  desflurane   \n",
       "35  Halogenated volatile anesthetics or depolarizi...  desflurane   \n",
       "36  Halogenated volatile anesthetics or depolarizi...  desflurane   \n",
       "37  Halogenated volatile anesthetics or depolarizi...  desflurane   \n",
       "38  Halogenated volatile anesthetics or depolarizi...  desflurane   \n",
       "39  Halogenated volatile anesthetics or depolarizi...  desflurane   \n",
       "40  Halogenated volatile anesthetics or depolarizi...  desflurane   \n",
       "41  Halogenated volatile anesthetics or depolarizi...  desflurane   \n",
       "42  Halogenated volatile anesthetics or depolarizi...  desflurane   \n",
       "43  Halogenated volatile anesthetics or depolarizi...  desflurane   \n",
       "44  Halogenated volatile anesthetics or depolarizi...  desflurane   \n",
       "45  Halogenated volatile anesthetics or depolarizi...  desflurane   \n",
       "46  Halogenated volatile anesthetics or depolarizi...  desflurane   \n",
       "47  Halogenated volatile anesthetics or depolarizi...  desflurane   \n",
       "48  Halogenated volatile anesthetics or depolarizi...  desflurane   \n",
       "\n",
       "      organization          title  \\\n",
       "0   CPIC_Guideline  November 2018   \n",
       "1   CPIC_Guideline  November 2018   \n",
       "2   CPIC_Guideline  November 2018   \n",
       "3   CPIC_Guideline  November 2018   \n",
       "4   CPIC_Guideline  November 2018   \n",
       "5   CPIC_Guideline  November 2018   \n",
       "6   CPIC_Guideline  November 2018   \n",
       "7   CPIC_Guideline  November 2018   \n",
       "8   CPIC_Guideline  November 2018   \n",
       "9   CPIC_Guideline  November 2018   \n",
       "10  CPIC_Guideline  November 2018   \n",
       "11  CPIC_Guideline  November 2018   \n",
       "12  CPIC_Guideline  November 2018   \n",
       "13  CPIC_Guideline  November 2018   \n",
       "14  CPIC_Guideline  November 2018   \n",
       "15  CPIC_Guideline  November 2018   \n",
       "16  CPIC_Guideline  November 2018   \n",
       "17  CPIC_Guideline  November 2018   \n",
       "18  CPIC_Guideline  November 2018   \n",
       "19  CPIC_Guideline  November 2018   \n",
       "20  CPIC_Guideline  November 2018   \n",
       "21  CPIC_Guideline  November 2018   \n",
       "22  CPIC_Guideline  November 2018   \n",
       "23  CPIC_Guideline  November 2018   \n",
       "24  CPIC_Guideline  November 2018   \n",
       "25  CPIC_Guideline  November 2018   \n",
       "26  CPIC_Guideline  November 2018   \n",
       "27  CPIC_Guideline  November 2018   \n",
       "28  CPIC_Guideline  November 2018   \n",
       "29  CPIC_Guideline  November 2018   \n",
       "30  CPIC_Guideline  November 2018   \n",
       "31  CPIC_Guideline  November 2018   \n",
       "32  CPIC_Guideline  November 2018   \n",
       "33  CPIC_Guideline  November 2018   \n",
       "34  CPIC_Guideline  November 2018   \n",
       "35  CPIC_Guideline  November 2018   \n",
       "36  CPIC_Guideline  November 2018   \n",
       "37  CPIC_Guideline  November 2018   \n",
       "38  CPIC_Guideline  November 2018   \n",
       "39  CPIC_Guideline  November 2018   \n",
       "40  CPIC_Guideline  November 2018   \n",
       "41  CPIC_Guideline  November 2018   \n",
       "42  CPIC_Guideline  November 2018   \n",
       "43  CPIC_Guideline  November 2018   \n",
       "44  CPIC_Guideline  November 2018   \n",
       "45  CPIC_Guideline  November 2018   \n",
       "46  CPIC_Guideline  November 2018   \n",
       "47  CPIC_Guideline  November 2018   \n",
       "48  CPIC_Guideline  November 2018   \n",
       "\n",
       "                                                 link data_source update_date  \n",
       "0   https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05  \n",
       "1   https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05  \n",
       "2   https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05  \n",
       "3   https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05  \n",
       "4   https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05  \n",
       "5   https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05  \n",
       "6   https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05  \n",
       "7   https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05  \n",
       "8   https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05  \n",
       "9   https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05  \n",
       "10  https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05  \n",
       "11  https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05  \n",
       "12  https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05  \n",
       "13  https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05  \n",
       "14  https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05  \n",
       "15  https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05  \n",
       "16  https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05  \n",
       "17  https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05  \n",
       "18  https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05  \n",
       "19  https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05  \n",
       "20  https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05  \n",
       "21  https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05  \n",
       "22  https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05  \n",
       "23  https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05  \n",
       "24  https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05  \n",
       "25  https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05  \n",
       "26  https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05  \n",
       "27  https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05  \n",
       "28  https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05  \n",
       "29  https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05  \n",
       "30  https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05  \n",
       "31  https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05  \n",
       "32  https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05  \n",
       "33  https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05  \n",
       "34  https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05  \n",
       "35  https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05  \n",
       "36  https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05  \n",
       "37  https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05  \n",
       "38  https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05  \n",
       "39  https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05  \n",
       "40  https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05  \n",
       "41  https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05  \n",
       "42  https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05  \n",
       "43  https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05  \n",
       "44  https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05  \n",
       "45  https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05  \n",
       "46  https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05  \n",
       "47  https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05  \n",
       "48  https://pharmgkb.org/guidelineAnnotation/PA166...  guildeline  2021-10-05  "
      ]
     },
     "execution_count": 33,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_haplotype_guideline"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "02eb2400",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.6.13"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
